



HAL
open science

HIV-1, HAART and cancer: a complex relationship

Anna Shmakova, Diego Germini, Yegor Vassetzky

► **To cite this version:**

Anna Shmakova, Diego Germini, Yegor Vassetzky. HIV-1, HAART and cancer: a complex relationship. International Journal of Cancer, 2019, 146, pp.2666 - 2679. 10.1002/IJC.32730 . hal-02323007

HAL Id: hal-02323007

<https://hal.science/hal-02323007>

Submitted on 18 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HIV-1, HAART and cancer: a complex relationship

Journal:	<i>International Journal of Cancer</i>
Manuscript ID	IJC-19-1407.R2
Wiley - Manuscript type:	Mini Review
Date Submitted by the Author:	n/a
Complete List of Authors:	Shmakova, Anna A.; Lomonosov Moscow State University Faculty of Fundamental Medicine, Germini, Diego; Institut Gustave-Roussy, CNRS UMR8126 Vassetzky, Yegor; Institut Gustave-Roussy, CNRS UMR8126
Key Words:	HIV-1, AIDS, Cancer, HAART, Anticancer drugs

SCHOLARONE™
Manuscripts

HIV-1, HAART and cancer: a complex relationship

Dr. Anna Shmakova^{1,2,3}, Dr. Diego Germini^{1,2}, Dr. Yegor Vassetzky^{1,2,4,5}

¹UMR 8126, CNRS, Univ. Paris-Sud, Université Paris Saclay, Institut Gustave Roussy, 114, rue Édouard-Vaillant F-94805 Villejuif, France

²LIA 1066 LFR2O French-Russian Joint Cancer Research Laboratory, 114, rue Édouard-Vaillant, 94805 Villejuif, France

³Laboratory of Gene and Cell Technologies, Faculty of Medicine, Lomonosov Moscow State University, 27 Lomonosovskiy Pr., bldg. 1, 119991 Moscow, Russia

⁴Koltzov Institute of Developmental Biology, 26 Vavilova str., 117334 Moscow, Russia

⁵To whom correspondence should be addressed: Dr. Yegor Vassetzky, UMR 8126, CNRS, Univ. Paris-Sud, Université Paris Saclay, Institut Gustave Roussy, 114, rue Édouard-Vaillant F-94805 Villejuif, France; Tél. : +33 (0)1 42 11 48 90, e-mail : yegor.vassetzky@cnrs.fr

Keywords: HIV-1, AIDS, cancer, HAART, anticancer drugs

List of abbreviations

AIDS, acquired immune deficiency syndrome
CCR5, C-C chemokine receptor type 5
EBV, Epstein–Barr virus
HAART, highly active antiretroviral therapy
HHV, human herpes virus
HIV, human immunodeficiency virus
HPV, human papillomavirus
HBV, hepatitis B virus
HCV, hepatitis C virus,
INSTI, HIV-integrase strand transfer inhibitor
KS, Kaposi sarcoma
LINE-1, long interspersed nuclear element-1
MMP, matrix metalloproteinases
NHL, non-Hodgkin lymphoma
NNRTI, non-nucleoside reverse transcriptase inhibitor
NRTI, nucleoside reverse transcriptase inhibitor

1
2
3 PI, HIV-protease inhibitor
4 PI3K, phosphatidylinositol 3-kinase
5 PSA, prostate-specific antigen
6 VEGF, vascular endothelial growth factor
7
8
9

10 **Declarations**

11 **Authors' contributions**

12 All authors equally contributed to the manuscript. All authors read and approved the final
13 manuscript

14 **Declaration of interests**

15 The authors declare that they have no conflict of interests

16 **Availability of data and material**

17 All data generated or analyzed during this study are included in this published article

18 **Acknowledgments**

19 This work was supported by grants from Plan Cancer (ENVIBURKITT), ANRS and LNCC to
20 YV. AS was supported by a short-term fellowship from the Boehringer Ingelheim Fonds. These
21 funding sources had no role in the writing of the manuscript or the decision to submit it for
22 publication. YV confirms having full access to all the data in the study and having final
23 responsibility for the decision to submit for publication.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

HIV infected people are at higher risk of developing cancer, although it is globally diminished in the era of highly active antiretroviral treatment (HAART). Recently, antioncogenic properties of some HAART drugs were discovered. We discuss the role of HAART in the prevention and improvement of treatment outcomes of cancers in HIV-infected people. We describe different trends in HAART-cancer relationships: cancer-predisposing as well as cancer-preventing. We cover the roles of particular drug regimens in cancer prevention. We also describe the cases of cancer treatment with HAART drugs in HIV-negative people, including ongoing clinical studies that may directly point to a possible independent anti-oncogenic activity of HAART drugs. We conclude that despite potent antioncogenic activities of every class of HAART drugs reported in preclinical models, the evidence to date indicates that their independent clinical impact in HIV-infected people is limited. Improved cancer prevention strategies besides HAART are needed to reduce HIV-cancer-related mortality.

Introduction

The introduction of highly active antiretroviral therapy (HAART) in 1996 has profoundly modified the overall survival rates of people with HIV/AIDS. HAART suppresses viral replication, restores the immunity and reduces the mortality,¹ but even in the era of HAART, HIV-infected individuals still have a higher risk of developing cancer compared to healthy individuals. They also have a more severe clinical course of cancer and lower survival rate compared to the non-infected population.^{2,3} In HIV+ patients, 10-20% of all deaths are attributable to cancer.^{4,5}

Given the higher risks for HIV-positive population, developing cancer control strategies for this group is a rising challenge to public health. To provide the context for further research, we will discuss clinical aspects related to the cancer burden in patients with HIV-infection and highlight details on the role of antiretroviral drugs in the development of cancer, which is not limited to viral suppression. Preclinical studies have shown that many antiretroviral drugs could exert anti-tumor effects independently of their capacity to suppress viral replication and reconstitute the immune system. Understanding the role of HAART in HIV-cancer relationship is important to optimize cancer prevention strategies, screening and clinical management of people with HIV infection. The present review also discusses the clinical impact of antiretroviral treatment in terms of cancer.

Search strategy and selection criteria

The review is based on the works referenced in MEDLINE, EBSCO OpenDissertations, Cochrane Library, Web of Science, Scopus, Embase, ScienceDirect and Google scholar from January 1, 1996 to December 1, 2018. We also analyzed registers of clinical trials (Cochrane Central Register of Controlled Trials (CENTRAL); ClinicalTrials.gov), abstracts of scientific meetings related to cancer and reference lists of included studies relevant to the subject of the

1
2 review. The search terms were “highly active antiretroviral therapy”, “HIV protease inhibitors”,
3
4 “HIV reverse transcriptase inhibitors”, “CCR5 receptor antagonists”, “HIV integrase inhibitors”
5
6 and “cancer/neoplasms”. The language of records was limited to English. The final reference list
7
8 was generated on the basis of originality and relevance to the broad scope of this Review.
9

10 11 12 **HIV and cancer risks in the HAART era**

13
14
15
16 HAART contributed to a slight reduction in overall cancer rates in HIV-infected people.⁶⁻⁸
17
18 Nevertheless, nowadays people living with HIV still have a 1.6-1.7-fold greater overall risk of
19
20 cancer development relative to the general population,^{8,9} and the risk is rising with age.¹⁰ This
21
22 fact can be explained by predisposing factors such as immunosuppression combined with
23
24 chronic inflammation due to virus persistence.^{11,12} HIV-infected population is also more
25
26 susceptible to cancer risk behavior (men who have sex with men, intravenous drug use, heavy
27
28 alcohol consumption, smoking) than general population and is prone to frequent coinfection with
29
30 other oncogenic viruses (Epstein Barr Virus (EBV), Human Herpesvirus Virus 8 (HHV-8),
31
32 Human Papilloma Virus (HPV), Hepatitis B and C Viruses (HBV, HCV)) exacerbated by loss of
33
34 immune control.^{11,12} This results in a cumulative greater probability of cancer development.
35
36 Some of these risk factors are modifiable. Highly active antiretroviral therapy (HAART) restores
37
38 the immunity and suppresses viral replication,¹ it was also shown to possess preclinical
39
40 antioncogenic activity, which will be discussed below (Fig. 1).
41
42
43
44
45
46

47
48 Prevalence of these risk factors among people with HIV infection indicates a vital need
49
50 for risk factor reduction efforts,¹³ including a possible pharmacological intervention. Indeed, a
51
52 combination of HIV and cancer produces a synergistic effect on mortality rates, which become
53
54 significantly higher than mortality rates for each disease taken separately.³
55
56

57
58 AIDS-defining cancers (ADCs: Kaposi's sarcoma, non-Hodgkin's lymphoma (NHL), invasive
59
60 cervical cancer) are traditionally distinguished in HIV-infected patients; other cancers are

1
2 referred to as non-AIDS defining cancers (NADCs).¹⁴ NADCs, in turn, are usually classified into
3
4 virus-related cancers (HPV-, EBV-, HCV-related cancers) and virus-unrelated cancers.
5
6

7 8 *ADCs*

9
10
11 HAART contributed to a significant decline in the incidence of ADCs, the outcome of such
12
13 cancers has improved and mortality has decreased.^{8,15-18} However, the risks for developing all
14
15 ADCs are still largely elevated in HIV-infected people; this risk is proportional to the HIV load
16
17 and inversely proportional to the CD4 cell count (Fig. 1).^{19,20} Immunosuppression is a strong
18
19 predictor for ADCs. For Burkitt's lymphoma, albeit, immune reconstitution is supposed to be, at
20
21 certain CD4 cell counts, a risk factor for the development of lymphoma, indicating a more
22
23 complex relationship with the immune status.²¹⁻²³ Consistently, it was shown that the incidence
24
25 of Burkitt's lymphoma is either rising in the HAART era,^{24,25} or remains stable over time^{9,23} as
26
27 opposed to other NHLs; the proportion of Burkitt's lymphoma among NHLs is growing.²⁶
28
29
30
31

32 33 *NADCs*

34
35
36 The number of all non-AIDS defining cancers (NADCs) is increasing since 1996 compared to
37
38 the pre-HAART era and is expected to continue to rise.^{27,28} Both virus-related and virus-
39
40 unrelated cancers contribute to this trend.²⁹ NADCs represent approximately 2/3 of all cancers in
41
42 HIV-patients; they are two times more frequent than ADCs.^{9,11} The rise of NADCs in the
43
44 HAART era is in part linked to the overall aging of people with HIV, this provides more time for
45
46 cancer to evolve.^{11,29} Contrary to ADCs, the association of risk of NADCs and CD4 counts or
47
48 HIV load is still a matter of discussion, as some researchers suppose they are not related,³⁰ while
49
50 others have shown that immunodeficiency was a risk factor associated with NADCs incidence.<sup>31-
51
52
53
54
55
56
57
58
59
60</sup>
³⁴ It appears that low CD4 cell count is a specific risk factor exclusively for virus-related
NADCs, but not for virus-unrelated ones,³⁴ e.g. CD4 counts are significantly higher in HIV+

1
2 patients that develop prostate cancer compared to HIV+ patients without cancer, indicating that
3
4 lower CD4 counts are possibly associated with less prostate cancer risk.³⁵
5
6
7

8 The overall incidence of NADCs in HIV-positive individuals was shown to be up to two times
9
10 higher compared to the general population and it remains basically unchanged during the
11
12 HAART era.^{2,8,9} This elevated incidence is mainly due to virus-related NADCs, which are five
13
14 times more frequent in HIV-infected people: Hepatitis B Virus (HBV)/HCV-related
15
16 hepatocellular carcinoma, HPV-related oropharyngeal cancers, HPV-related anal cancer, EBV-
17
18 related classical Hodgkin lymphoma, and others.⁹ Some virus-unrelated NADCs: lung, larynx,
19
20 nasal cavity cancers also occur more frequently in HIV-infected people;⁹ this effect can be
21
22 partially explained by the prevalence of smokers.^{36,37} Smoking cessation should be discussed
23
24 with patients to reduce cancer risk (Fig. 1).³⁸
25
26
27
28

29 Interestingly, for some reasons, some cancers are significantly more rare in HIV-infected
30
31 patients compared to the general population.⁹ They include stomach, colorectal, kidney, uterus,
32
33 prostate, breast, brain, thyroid cancers.^{9,39-41} This cannot be solely explained by targeted cancer
34
35 screening for these types of cancer (mammography, colon-/sigmoidoscopy, PSA test)³⁹ or
36
37 hormone levels alteration due to HIV infection.⁴² Overweight/obesity is less prevalent in people
38
39 living with HIV than in general population, and that is a proposed risk factor for gastrointestinal
40
41 tract tumors, breast, endometrial and renal cancers.^{13,43} This requires further investigation with a
42
43 direct comparison of HIV-infected people with body mass index-matched uninfected people.
44
45
46 These trends may also be due to viral-host interaction. It is a common knowledge that HIV
47
48 induces T-cell apoptosis.⁴⁴⁻⁴⁶ Several studies have shown that HIV-1 and its molecules (gp120,
49
50 Nef) can also mediate neuroblastoma,⁴⁷ breast,⁴⁸ colorectal,^{49,50} prostate⁵¹ cancer cell growth
51
52 inhibition, and apoptosis. An interesting possibility, explaining lower frequency of several
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

cancers in HIV-infected persons, is that the HAART drugs can possess cancer-prevention or antineoplastic activity. Below we shall consider recent data on this subject.

HIV and cancer treatment in the HAART era

During the HAART era, cancer-contributable mortality is higher in patients with HIV compared to non-infected population even when clinical features are similar, and HIV-infected people diagnosed with cancer experience excess mortality that exceeds the expected mortality from a simple combination of HIV and cancer.^{3,52-54} Cancer treatment in people living with HIV/AIDS is challenging due to the absence of clinical recommendations or established protocols and lack of clinical experience.⁵⁵ A significantly higher proportion of HIV-infected individuals does not receive treatment for diffuse large B-cell lymphoma, lung cancer, Hodgkin's lymphoma, prostate cancer, and colorectal cancer. HIV infection is associated with a lack of standard treatment modality for local-stage diffuse large B-cell lymphoma, non-small-cell lung cancer, and colon cancer.⁵⁵

ADCs

The introduction of HAART has significantly improved survival rates for ADCs,⁵⁶ nevertheless, HIV infection seems to remain a factor increasing the risk of death in patients with ADCs. The overall survival of HIV-infected patients with NHLs and cervical cancer is significantly lower than in HIV-negative population.^{57,58}

ADCs give better responses to treatment with the HAART + chemotherapy/radiotherapy combination rather than HAART alone or chemotherapy/radiotherapy alone,⁵⁹⁻⁶³ therefore, HAART use is recommended for patients with ADCs.¹⁴ No difference was found between PI-based HAART versus other regimens in treatment outcomes of Kaposi's sarcoma⁶⁴ and NHL^{65,66} in a combination with chemotherapy. Even HAART treatment alone without chemotherapy can

1
2 lead to positive outcomes of Kaposi's sarcoma,⁶⁷⁻⁷⁰ NHLs,⁷¹⁻⁷⁴ oncogenic cervical squamous
3 intra-epithelial lesions.^{75,76} Nonetheless, a further clinical study proved that HAART +
4 chemotherapy combination gave a better response than HAART alone, albeit no difference in the
5 survival rate was revealed.⁷⁷ At the same time, a PI-based regimen was revealed to be associated
6 with higher toxicity during chemotherapy of lymphomas.⁶⁶ Patients with lymphomas receiving
7 PI-based HAART had a significantly lower 1-year survival compared to NNRTI-based HAART
8 probably due to toxicity.⁷⁸ Burkitt's lymphoma is again a puzzling exception among NHLs, since
9 its outcome is still rather poor in the HAART era.^{79,80}

21 *NADCs*

22
23
24
25 In the HAART era survival rates for HLs and anal cancer improved considerably.⁵⁶ The overall
26 3-year survival of HIV-infected patients with HLs is significantly lower than in HIV-negative
27 population,⁵⁷ which might be due to treatment disparities.⁸¹ For solid tumors, such as lung, liver,
28 anal cancer five-year survival is comparable to that in general population.^{56,82}

29
30
31
32 Promising results were obtained in several reports of NADCs treatment in HIV-infected people
33 with HAART-drugs alone or in combination with chemotherapy, which resulted in a good
34 clinical response.⁸³⁻⁸⁷

35 *Combination of HAART and chemotherapy*

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
HIV-infected people are generally excluded from clinical trials; therefore data on toxicity,
outcomes and possible drug interactions during cancer treatment are limited. Despite the
increased toxicity and drug-drug interactions, HAART withdrawal during chemotherapy is
unfavorable in HIV-patients with cancer and can lead to a poorer outcome;⁸⁸ therefore in
general, any HAART interruption is not advisable during cancer treatment.³⁸ Possible drug-drug
interactions should be therefore carefully assessed when treating cancer in HIV-infected patients.

1
2
3 Drug-drug interactions rely on many factors, such as the route of elimination, the effect on
4 enzymes and transporters involved in the drug metabolism. Both HAART and antineoplastic
5 drugs can be metabolized by CYP450 enzyme family and serve as CYP450 inhibitors, which can
6 lead to drug accumulation and potential toxicity, or as CYP450 inducers, which leads to drug
7 elimination and decreased efficacy, except for active metabolites of several drugs.^{38,89} As an
8 example, ritonavir*, a PI and a potent CYP3A4 inhibitor, was reported to be associated with
9 more severe toxicity in combination with chemotherapy compared to non-ritonavir-based
10 HAART.⁸⁸ On the contrary, NNRTIs are mainly CYP3A inducers.⁸⁹ HAART regimen should be
11 modified when facing undesirable drug-drug interactions or elevated toxicity.³⁸ In this case,
12 preference can be given to the INSTI-based regimen, which is supposed to be relatively safe.^{38,90}
13 Both NNRTIs and INSTIs are superior to PIs in terms of viral suppression in HIV-infected
14 patients with malignancies.⁹⁰ Regarding the complexity of multidrug interaction, if a patient is
15 HAART-naive, it is recommended to start HAART more than a week before or after the cancer
16 treatment in order to differentiate between adverse effects.³⁸ It is also recommended that
17 clinicians consult major reviews dedicated to the topic of potential drug-drug interactions
18 between HAART and chemotherapeutic drugs,^{89,91,92} treatment guidelines,³⁸ and refer to
19 available resources such as <http://www.hiv-druginteractions.org> to optimize clinical management
20 of HIV-infected patients with cancer and increase therapeutic benefit.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 An individual pharmacogenetic profile is another factor that influences patients' response to drug
46 combinations. A promising strategy is to evaluate personalized pharmacogenomic profile to
47 predict efficacy and undesirable adverse effects of the therapeutic agents when planning HAART
48 and chemotherapy regimens.⁹³
49
50
51
52
53
54
55
56
57

58 * Ritonavir is currently recommended to improve the pharmacokinetic profiles of other
59 antiretroviral drugs (pharmacokinetic booster), not as an independent HAART component.^{94,198}
60

1
2 Thus, cancer treatment in people with HIV requires both an adequate control of HIV infection by
3 HAART and an individual drug-drug interaction assessment.
4
5
6
7

8 **HAART and cancer prevention**

9

10
11 HAART is defined as the use of several (at least three, rarely two) antiretroviral drugs and has
12 different regimens: two nucleoside reverse transcriptase inhibitors (NRTIs) in combination with
13 a third drug from one of three drug classes: HIV-integrase strand transfer inhibitors (INSTIs),
14 non-nucleoside reverse transcriptase inhibitors (NNRTI), or HIV-protease inhibitors (PIs) are
15 currently recommended.⁹⁴
16
17
18
19
20
21
22

23
24 In HIV-infected people, HAART use is definitely associated with lower cancer incidence over
25 no treatment for most cancers and particularly for ADCs.^{7,95,96} Whether this effect is based on
26 immune reconstitution and virus suppression, or it is an independent protective factor, remains
27 unclear. HAART use is considered to be a strong factor responsible for the decreased ADCs
28 occurrence in HIV-infected people and the greater cumulative exposure to HAART, the lower
29 the risk of ADCs is.⁹⁷ The protective effect of HAART is mainly explained by virus inhibition
30 and immune restoration. Although at first it was thought that HAART had an additional
31 protective effect independent of CD4 cell count and viral load,^{19,98–100} the latter studies did not
32 detect any independent effect of HAART on Kaposi sarcoma incidence after adjusting for more
33 variables and in a larger cohort.^{20,101}
34
35
36
37
38
39
40
41
42
43
44
45
46

47
48 HAART was first reported to be protective for NADCs,¹⁰² or to have no effect,⁶ nowadays the
49 use of HAART is associated with a higher rate of NADCs over no treatment and long cumulative
50 exposure to HAART is a predictor of NADCs risk.^{33,96,97,100} This effect is mainly driven by
51 virus-related cancers, as their incidence was significantly higher in people treated with
52 antiretrovirals compared to no antiretroviral treatment, while there was no change in virus-
53 unrelated cancer rates between HIV-infected people with or without antiretroviral therapy.¹⁰⁰
54
55
56
57
58
59
60

1
2 Improved survival of HIV-positive individuals during the HAART era may allow for sufficient
3 time for virus-associated lesions to develop into malignancies. For Hodgkin's lymphoma,
4 though, HAART use was not associated with higher cancer risk in large European cohort
5 studies.^{103–105} The absence of HAART was not proven to be an independent risk factor for
6 NADCs.¹⁹ HAART exposure did not play any role in lung cancer staging.¹⁰⁶ No association was
7 shown between HAART use and the risk of lung cancer.^{107,108} The opposite trend is observed in
8 prostate cancer, where the cumulative antiretroviral exposure decreases cancer risk, though no
9 difference was observed between people with or without antiretroviral therapy.¹⁰⁰ The role of
10 HAART in anal cancer prevention is ambiguous. HAART is associated with a lower prevalence
11 of anal intraepithelial neoplasia,¹⁰⁹ and it takes more time for anal cancer development in
12 HAART era than before,¹¹⁰ but treatment duration does not reduce anal cancer risk,¹¹¹ and
13 HAART is considered to be a risk factor for relapse of anal cancer.¹¹²

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31 A lack of specific and independent protective effect of HAART on cancer incidence, regardless
32 of their potent antitumor effect observed in preclinical studies (see below), may be explained by
33 low doses, sufficient for viral suppression, but insufficient for cancer prevention. These
34 relationships are further complicated by various factors. For example, the hepatotoxicity of
35 HAART may amplify the carcinogenic effect of HBV and HCV.¹¹³ NRTIs, a mandatory
36 component of main HAART regimens, were also considered to be genotoxic and
37 carcinogenic.¹¹⁴ However, large prospective cohort studies of HIV-negative children, perinatally
38 exposed to any drug of NRTI class, revealed no change in cancer incidence compared to non-
39 exposed ones and to the general population.^{115–118} They found, albeit, that the risk of cancer
40 development was significantly higher in those exposed to didanosine-lamivudine combination
41 than to zidovudine monotherapy.¹¹⁵ Later, it was found that didanosine exposure in HIV-
42 negative children was oncogenic and accounted for higher cancer risk.^{117,118} Didanosine use is
43 not currently recommended.⁹⁴

Comparison between HAART regimens in terms of cancer prevention

As HAART drugs have various mechanisms of action additionally to their main antiretroviral activity, their efficiency in cancer prevention can vary. Below we shall consider the association between HAART regimens and cancer risk.

ADCs

PI and NNRTI-based HAART were reported to have a similar protective effect on ADC incidence (Table 1).^{97,100,119} Ritonavir-based, indinavir[†]-based or nelfinavir*-based therapy confers no advantages compared to other PI- or NNRTI-based regimens in the prevention of ADCs.^{95,96,120} This is in line with the fact that the HAART impact on the decrease of ADCs is mainly connected with improvement in immune function and viral load.²⁰ At the same time, some studies showed potential advantages of PI-based HAART in ADCs prevention over other regimens. Only PI-containing HAART significantly reduces the frequency of HHV-8 detection compared to HAART-naïve patients.¹²¹ In patients with low immune activity, PI-based therapy is more efficient at inducing complete response than NNRTI-HAART.¹²² NNRTI-based HAART was shown to be associated with Kaposi's sarcoma relapse in a case series study (n = 5)¹²³ and in a small prospective cohort study (n = 45)¹²⁴, though the opposite was shown in another case series study (n = 24)¹²⁵. NNRTIs were shown to be more potent in reducing the risk of NHL.⁹⁷ The regimens other than PI- or NNRTI-based are less studied, however, there were two case report of human herpesvirus 8 (HHV8) viremia and Kaposi's sarcoma relapse after switching from a PI- to an INSTI-based HAART and rapid remission of Kaposi's sarcoma after returning back to PI-based therapy.^{126,127} A recent large cohort study found no evidence that INSTIs were

[†] Both indinavir and nelfinavir are no longer recommended accordingly to the latest guidelines of HIV treatment.⁹⁴

1
2 associated with increased cancer risk.¹²⁸ Treatment with the CCR5 antagonist (vicriviroc[‡]) can be
3
4 associated with the increased risk of developing cancers, including lymphomas,¹²⁹ but later
5
6 studies showed that the cancer incidence was similar between vicriviroc and placebo;¹³⁰
7
8 maraviroc from the same class was also confirmed to be relatively safe.¹³¹
9
10

11 12 *NADCs*

13
14
15
16 Several large cohort studies reported no difference between PI- and NNRTI-based regimens in
17
18 cancer prevention in all cancers except anal cancer (Table 1)^{95,96,100,132}. One study showed
19
20 NNRTI association with an increased risk of NADCs and precisely Hodgkin's lymphoma,² and
21
22 controversially, another study showed that overall NADCs incidence was higher in people
23
24 receiving PI-based HAART.⁹⁷ Moreover, the latter study reported that PI-based regimen did not
25
26 decrease the risk of Hodgkin lymphoma, while NNRTI-based HAART did.⁹⁷
27
28

29
30 PI-based HAART may be associated with an increased risk of anal cancer, whereas NNRTI use
31
32 has no association with anal cancer or is associated with a decreased risk.^{96,97,100,133,134}
33
34 Interestingly, nelfinavir-based HAART was not associated with a higher risk of anal cancer as
35
36 opposed to other PI-based regimens.⁹⁶ It was recently reported that adjustment for both CD4 cell
37
38 count and cumulative NRTI exposure abolished the association of PI-based regimen with anal
39
40 cancer risk in a case-control study.¹³⁵ On the other hand, PI use was associated with a lower risk
41
42 of prostate cancer,¹⁰⁰ which is consistent with the overall lower incidence of prostate cancer in
43
44 HIV-infected people compared to the general population. These trends remain difficult to
45
46 explain.
47
48
49
50

51
52 In conclusion, currently there is no evidence for any particular HAART regimen being more or
53
54 less associated with cancer risk for ADCs and virus-unrelated NADCs, except for a lower risk of
55
56

57
58 [‡] Phase III clinical trials were discontinued and vicriviroc was not approved for HIV
59
60 treatment.^{94,198}

1
2 prostate cancer with a PI-based HAART. Regarding virus-unrelated NADCs, PI-based HAART
3
4 is estimated to be associated with an increased risk of anal cancer and probably of Hodgkin
5
6 lymphoma.
7
8
9

10 **Preclinical antineoplastic activity of HAART drugs**

11
12
13 Recent preclinical studies showed that HAART drugs from different classes possessed potent
14
15 anti-oncogenic activity. The proposed mechanisms of their action are summarized in Fig. 2.
16
17

18
19 HIV-protease inhibitors (PIs) have pleiotropic pharmacological properties besides their
20
21 antiretroviral activity. They have been reported to inhibit the growth of various cancer cell lines
22
23 *in vitro* as well as tumors in *in vivo* xenografts models.^{136–139} PIs induce cell growth arrest,
24
25 endoplasmic reticulum stress, caspase-dependent apoptosis, autophagy (for review see ^{140–142}).
26
27 Moreover, PIs are known for their anti-angiogenic and radiosensitizing effects.^{141,143} PIs action is
28
29 associated with inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt pathway; one of the
30
31 possible mechanisms is binding to Hsp90 and inhibiting its chaperone function followed by
32
33 decreased PI3K/Akt signaling.^{137,138} Together and independently of each other, PI3K and its
34
35 downstream kinase Akt regulate various cell processes such as growth, proliferation, survival,
36
37 migration, apoptosis; and their hyperactivation is a cancer hallmark.^{144,145} PI3K/Akt signaling in
38
39 cancer inhibits apoptotic enzymes; promotes activation of mTOR and NF- κ B axes that regulate
40
41 transcription, increase cell growth, survival, proliferation, increase matrix metalloproteinases
42
43 (MMPs) and vascular endothelial growth factor (VEGF) expression, associated with migration
44
45 and angiogenesis, respectively; causes chemo-/radiotherapy resistance by misregulation of DNA
46
47 damage response.^{143,146–149} Akt, VEGF, MMPs and other important cancer-phenotype proteins
48
49 are partners of Hsp90, the latter works as a molecular chaperone and guarantees correct folding
50
51 of its substrates.¹⁵⁰ Hsp90 inhibition leads not only to targeted destabilization of key oncogenic
52
53
54
55
56
57
58
59
60

1
2 proteins but also to misfolded protein aggregation, endoplasmic reticulum stress, and apoptotic
3
4 death or autophagy.^{151,152}
5
6
7

8 Detailed docking analysis has shown that PIs can be potent Hsp90 inhibitors; their binding
9 capacity to Hsp90 decreases in the following order: Nelfinavir, Indinavir, Saquinavir, Ritonavir,
10 Lopinavir, Tipranavir, Darunavir, Amprenavir[§].¹⁵³ Indeed, among all PIs, nelfinavir seems to
11 have the highest anti-cancer activity.¹⁴¹ It is noteworthy that a longitudinal study of antitumor
12 effects of PIs and especially, nelfinavir, is nuanced by the fact that in 2007 Roche's Viracept
13 (nelfinavir mesylate) was discovered to be contaminated by a mutagenic compound.¹⁵⁴
14 Importantly, PIs can also directly inhibit the replication of human herpesvirus 8 (HHV8), the
15 etiological agent of Kaposi's sarcoma.^{121,155}
16
17
18
19
20
21
22
23
24
25
26

27 Though at first nucleoside reverse transcriptase inhibitors (NRTIs) were supposed to be
28 genotoxic, mutagenic and oncogenic due to their ability to incorporate into nuclear DNA and
29 directly inhibit cellular DNA polymerases,^{114,117,156,157} the subsequent clinical studies have shown
30 no clear correlation between NRTIs and cancer (see above). In fact, *in vitro* studies have shown,
31 that NRTIs might also possess anticancer activity,^{158–160} which is probably associated with their
32 capacity to inhibit DNA repair,¹⁶¹ induce mitochondrial toxicity,¹⁶² apoptosis, modulate activity
33 and expression of endogenous reverse transcriptase encoded by the long interspersed nuclear
34 element-1 (LINE-1).¹⁵⁸ LINE-1 propagation throughout the DNA may play a role in genome
35 instability, mutagenesis and contribute to carcinogenesis.¹⁶³
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Another HAART class, non-nucleoside reverse transcriptase inhibitors (NNRTIs) were also
50 demonstrated to inhibit the growth of cancer cell lines and xenografts in rodents,^{157,164–166} among
51 them, efavirenz is supposed to have the highest anticancer potential.¹⁶⁷ NNRTIs can act on
52 cancer cells through the induction of DNA damage,¹⁵⁷ apoptosis,¹⁶⁸ oxidative stress,¹⁶⁵ and
53
54
55
56
57

58 [§] Amprenavir production was discontinued, a prodrug fosamprenavir is available and
59 approved.^{94,198}
60

1
2 downregulation of LINE-1 expression.¹⁶⁹ Similarly to PIs, exposure to NNRTIs was associated
3
4 with the radiosensitizing effect.^{165,170}
5
6

7
8 HIV-integrase strand transfer inhibitors (INSTIs) may cause aberrant HIV-integration and
9
10 rearrangements in the host DNA when used in low doses.^{171,172} Low-dose INSTI may create the
11
12 situation when strand transfer reaction is blocked at only one of two ends of viral DNA, which
13
14 subsequently leads to mutation-prone integration of a blocked end *via* the host enzymes.¹⁷¹ Thus,
15
16 these drugs are potentially mutagenic and carcinogenic; however, there is no evidence for
17
18 increased cancer risk in patients exposed to INSTIs. INSTIs were also shown to inhibit a
19
20 metnase enzyme associated with chemotherapy resistance;¹⁷³ thus they can be potentially applied
21
22 together with antineoplastic drugs to increase their efficacy.
23
24
25

26
27 Finally, recent studies have shown that CCR5 antagonists are also potent antioncogenic and
28
29 antimetastatic effectors for various cancer cell lines and xenografts.^{174–178} CCR5 blockade results
30
31 in a decreased invasion, migration, metastatic potential cell proliferation, and leads to
32
33 proapoptotic signaling.^{174,176,179}
34
35

36
37 Thus, the preclinical data on HAART components point to its protective effect against cancer for
38
39 virtually every class of drug, which is very promising in terms of drug repositioning. Still, it is
40
41 important to reveal the causal impact of these drugs on humans who undergo HIV and/or cancer
42
43 treatment.
44
45

46 47 **Antiretroviral drugs and cancer treatment in HIV-negative patients**

48

49
50 As many *in vitro* studies have shown the anticancer activity of HAART drugs, they were
51
52 proposed for use in cancer treatment. In addition, the use of antiretroviral drugs in HIV-negative
53
54 people with cancer can help us evaluate a possible protective effect of HAART, independent of
55
56 its antiretroviral activity *per se*. The favorable treatment outcome of HIV-negative patients with
57
58
59
60

1
2
3 Kaposi's sarcoma treated with indinavir (PI) points to its direct antioncogenic properties in
4 ADCs.¹⁸⁰ At present, several clinical trials of antiretroviral drugs in cancer are underway. They
5
6 are summarized in Table 2. However, the data addressing this question are still limited, and the
7
8 results obtained from clinical trials are often inconclusive.
9

10
11
12 Promising results were obtained for nelfinavir (PI) as monotherapy or combined with
13
14 chemoradiotherapy in phase I clinical trials: in locally advanced pancreatic cancer,¹⁸¹ in locally
15
16 advanced non-small cell lung cancer,¹⁸² in locally advanced rectal cancer,¹⁸³ in multiple
17
18 myeloma,¹⁸⁴ in neuroendocrine tumors of the midgut or pancreatic origin,¹⁸⁵ and in glioblastoma
19
20 multiforme,¹⁸⁶ where the level of response was higher than reported before and the toxicity was
21
22 acceptable. A phase II clinical trial of nelfinavir added to bortezomib and dexamethasone in the
23
24 proteasome inhibitor-refractory multiple myeloma showed exceptional response rates (~65%).¹⁸⁴
25
26 A phase II clinical trial of nelfinavir combined with chemoradiation in locally advanced
27
28 inoperable pancreatic cancer showed improved tumor oxygenation and perfusion, which might
29
30 lead to better treatment response, however, the study was discontinued because of the
31
32 unavailability of nelfinavir in Europe.¹⁸⁷ Data from a phase I clinical trial of maraviroc (CCR5
33
34 antagonist) in advanced colorectal cancer with hepatic metastases showed a partial response in
35
36 patients with previously refractory disease.¹⁷⁹ Lopinavir/Ritonavir combination (PIs) was
37
38 successfully used for the treatment of HPV-positive high grade squamous intraepithelial lesions
39
40 in HIV-negative women.¹⁸⁸ There was also a case report of successful thyroid papillary
41
42 carcinoma treatment with a combination of Nevirapine (NNRTI) and radioiodine, resulting in re-
43
44 induction of cell differentiation, better drug uptake and sensitivity to treatment, slower
45
46 progression of the disease.^{189,190} However, definite conclusions cannot be drawn at this stage due
47
48 to a small number of patients, possible patient selection bias, and lack of control groups.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Some studies point to the absence of the anti-tumor activity of antiretroviral drugs. No meaningful improvement in clinical outcomes was reported among patients with recurrent adenoid cystic carcinomas and nelfinavir (PI) monotherapy in a phase II clinical trial.¹⁹¹ The use of efavirenz (NNRTI) also did not improve the non-progression rate of castration-resistant prostate cancer in a phase II clinical trial.¹⁹² A phase II clinical trial of ritonavir/lopinavir (PIs) combination in patients with progressive or recurrent high-grade gliomas did not reveal a potent clinical activity either.¹⁹³ These results can be explained by low effectivity of these drugs as monotherapy, by low plasma concentrations of drugs, or their low tissue concentrations due to poor access to the tumor. Therefore, even though some results concerning the use of antiretroviral drugs in cancer treatment are promising, further studies, investigating higher dosage of the drugs and combinations with chemoradiotherapy, are necessary to assess their effectiveness in the treatment of different types of cancer and will provide insight into optimal oncological doses of HAART drugs.

Conclusions

HIV-associated cancers are a serious health problem leading to rising mortality in an HIV-infected population, therefore cancer prevention and cancer control strategies are required. The main trends in cancer incidence relative to HAART treatment are summarized in Table 3. The main protective effect of HAART in HIV-infected people is related to ADCs and may be explained by immune reconstitution and viral suppression. The effect of HAART in NADCs is more complex and nuanced. Interestingly, the difference between HAART regimens in cancer prevention is observed only for virus-related cancers, where PI-based HAART is less favorable than other regimens. The role of HAART during cancer treatment is positive, though it may be complicated by drug-drug interactions. The later should be carefully assessed by clinicians when planning the cancer treatment in HIV-infected people. Doctors should also take measures to

1
2 reduce risk behavior in people with HIV (smoking and alcohol consumption cessation), as a
3 cancer prevention strategy and during cancer treatment. PI-based HAART is not preferred during
4 cancer treatment as well, because of suboptimal viral suppression in patients with HIV and
5 cancer.
6
7
8
9

10
11 Antiretroviral drugs that are in use since many years were recently shown to be potentially
12 antineoplastic and therefore may present an elegant solution for cancer control in this population.
13
14

15 The plethora of published articles studied their effects in primary cells, tumor cell lines, and
16 tumor xenografts models, however, their effect on cancer prevention, treatment and outcome in
17 humans remains poorly understood. Here, we summarized and discussed all potential clinical
18 aspects related to the impact of antiretroviral treatment on cancer.
19
20
21
22
23
24
25

26
27 Finally, several reports of HAART use in cancer treatment in the HIV-negative population may
28 help answer the question about an antioncogenic activity of HAART, but to date, the data from
29 clinical studies are still limited. It is possible that some modifications or optimizations of
30 HAART regimens are required in order to observe antioncogenic and cancer-protective
31 properties of these drugs in clinical practice.
32
33
34
35
36
37
38
39

40 Many epidemiological studies exploring HIV-cancer relationships have a common limitation:
41 they lack the information on antiretroviral therapy, thus a potentially promising question about
42 the relationships between HAART and cancer risks and outcomes remains unanswered. The
43 absence of clinical recommendations, together with a lack of experience regarding cancer
44 prevention or simultaneous treatment of HIV and cancer and substandard cancer care, indicates
45 an urgent need for large-scale epidemiological studies addressing the question about the effect of
46 particular HAART drugs and their dosage on cancer prevention. Furthermore, inclusion of
47 people with HIV in clinical trials of antineoplastic treatments should be encouraged.
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. HIV-CAUSAL Collaboration, Ray M, Logan R, Sterne JAC, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. *AIDS* 2010; 24(1): 123–137
2. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Møller H, Bower M. Highly Active Antiretroviral Therapy and the Incidence of Non–AIDS-Defining Cancers in People With HIV Infection. *J Clin Oncol* 2009; 27(6): 884–890
3. Coghill AE, Shiels MS, Suneja G, Engels EA. Elevated cancer-specific mortality among HIV-infected patients in the United States. *J Clin Oncol* 2015; 33(21): 2376–2383
4. Engels EA, Yanik EL, Wheeler W, Gill MJ, Shiels MS, Dubrow R, Althoff KN, Silverberg MJ, Brooks JT, Kitahata MM, Goedert JJ, Grover S, Mayor AM, Moore RD, Park LS, Rachlis AR, Sigel K, Sterling TR, Thorne JE, Pfeiffer RM, And NAACC on R, Design of the International Epidemiologic Databases to Evaluate AIDS for the NAACC on R and D of the IED to E, Design NAACC on R and, AIDS of the IED to E, Benson CA, Bosch RJ, Kirk GD, Boswell S, Mayer KH, Grasso C, Hogg RS, Harrigan PR, Montaner JSG, Yip B, Zhu J, Salters K, Gabler K, Buchacz K, Brooks JT, Gebo KA, Moore RD, Moore RD, Carey JT, Rodriguez B, Horberg MA, Silverberg MJ, Thorne JE, Rabkin C, Jacobson LP, D'Souza G, Klein MB, Rourke SB, Rachlis AR, Gliberman J, Kopansky-Giles M, Hunter-Mellado RF, Mayor AM, Gill MJ, Deeks SG, Martin JN, Patel P, Brooks JT, Saag MS, Mugavero MJ, Willig J, Eron JJ, Napravnik S, Kitahata MM, Crane HM, Drozd DR, Sterling TR, Haas D, Rebeiro P, Turner M, Bebawy S, Rogers B, Justice AC, Dubrow R, Fiellin D, Gange SJ, Anastos K, Moore RD, Saag MS, Gange SJ, Kitahata MM, Althoff KN, McKaig RG, Freeman AM, Moore RD, Freeman AM, Lent C, Kitahata MM, Van Rompaey SE, Crane HM, Drozd DR, Morton L, McReynolds J, Lober WB, Gange SJ, Althoff KN, Abraham AG, Lau B, Zhang J, Jing J, Modur S, Wong C, Hogan B, Desir F, Liu B, You B. Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. 2017; 65(4): 636–643
5. Goehringer F, Bonnet F, Salmon D, Cacoub P, Paye A, Chene G, Morlat P, May T, Chêne G, Morlat P, May T. Causes of Death in HIV-Infected Individuals with Immunovirologic Success in a National Prospective Survey. *AIDS Res Hum Retroviruses* 2017; 33(2): 187-193
6. Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Agan BK, Wegner S. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. *AIDS* 2009; 23(1): 41–50
7. Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, Bouchardy C, Dehler S, Jundt G, Ess S, Bordoni A, Konzelmann I, Frick H, Dal Maso L, Elzi L, Furrer H, Calmy A, Cavassini M, Ledergerber B, Keiser O, Swiss HIV Cohort Study the SHC. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. *Br J Cancer* 2010; 103(3): 416–422
8. Park LS, Tate JP, Sigel K, Rimland D, Crothers K, Gibert C, Rodriguez-Barradas MC, Goetz MB, Bedimo RJ, Brown ST, et. Justice AC, Dubrow R. Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997–2012. *AIDS* 2016; 30(11): 1795-1806
9. Hernández-Ramírez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. *Lancet HIV* 2017; 4(11): e495–e504
10. Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, Bertisch B, Bernasconi E, Weber R, Swiss HIV Cohort Study. Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study. *Clin Infect Dis* 2011; 53(11): 1130–1139
11. Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA. Excess Cancers Among HIV-Infected People in the United States. *JNCI J Natl Cancer Inst* 2015; 107(4)
12. Hart BB, Nordell AD, Okulicz JF, Palfreeman A, Horban A, Kedem E, Neuhaus J, Jacobs DR, Duprez DA, Neaton JD, INSIGHT SMART and ESPRIT Groups. Inflammation Related Morbidity and Mortality Among HIV-Positive Adults. *JAIDS J Acquir Immune Defic Syndr* 2017; 77(1): 1
13. Park LS, Hernández-Ramírez RU, Silverberg MJ, Crothers K, Dubrow R. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. *AIDS* 2016; 30(2): 273–291
14. Berretta M, Di Francia R, Stanzione B, Facchini G, LLeshi A, De Paoli P, Spina M, Tirelli U. New treatment strategies for HIV-positive cancer patients undergoing antitubercular chemotherapy. *Expert Opin Pharmacother* 2016; 17(18): 2391–2403
15. Franceschi S, Maso LD, Rickenbach M, Polesel J, Hirschel B, Cavassini M, Bordoni A, Elzi L, Ess S, Jundt G, Mueller N, Clifford GM. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. *Br J Cancer* 2008; 99(5): 800–804
16. Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, Bouchardy C, Furrer H, Hasse B, Levi F,

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Probst-Hensch NM, Schmid P, Franceschi S, Swiss HIV Cohort Study. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. *AIDS* 2008; 22(2): 301–306
17. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S, Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. *J Natl Cancer Inst* 2005; 97(6): 425–432
 18. Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. *Curr Opin HIV AIDS* 2017; 12(1): 6–11
 19. Guiguet M, Boué F, Cadranet J, Lang J-M, Rosenthal E, Costagliola D, Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. *Lancet Oncol* 2009; 10(12): 1152–1159
 20. Dubrow R, Qin L, Lin H, Hernández-Ramírez RU, Neugebauer RS, Leyden W, Althoff KN, Achenbach CJ, Hessel NA, Modur SP, D'Souza G, Bosch RJ, Grover S, Horberg MA, Kitahata MM, Mayor AM, Novak RM, Rabkin CS, Sterling TR, Goedert JJ, Justice AC, Engels EA, Moore RD, Silverberg MJ, North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS. Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. *J Acquir Immune Defic Syndr* 2017; 75(4): 382–390
 21. Guech-Ongey M, Simard EP, Anderson WF, Engels EA, Bhatia K, Devesa SS, Mbulaiteye SM. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? *Blood* 2010; 116(25): 5600–5604
 22. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. *Pathologica* 2010; 102(3): 83–87
 23. Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. *AIDS* 2014; 28(15): 2313–2318
 24. Howlader N, Shiels MS, Mariotto AB, Engels EA. Contributions of HIV to Non-Hodgkin Lymphoma Mortality Trends in the United States. *Cancer Epidemiol Biomarkers Prev* 2016; 25(9): 1289–1296
 25. Hishima T, Oyaizu N, Fujii T, Tachikawa N, Ajisawa A, Negishi M, Nakamura T, Iwamoto A, Hayashi Y, Matsubara D, Sasao Y, Kimura S, Kikuchi Y, Teruya K, Yasuoka A, Oka S, Saito K, Mori S, Funata N, Sata T, Katano H. Decrease in Epstein–Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy. *Microbes Infect* 2006; 8(5): 1301–1307
 26. Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, Burkholder GA, Reid EG, Rodriguez B, Deeks SG, Mayer KH, Moore RD, Kitahata MM, Eron JJ, Richards KL. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. *J Natl Cancer Inst* 2013; 105(16): 1221–1229
 27. Shiels MS, Islam JY, Rosenberg PS, Hall HI, Jacobson E, Engels EA. Projected Cancer Incidence Rates and Burden of Incident Cancer Cases in HIV-Infected Adults in the United States Through 2030. *Ann Intern Med* 2018; 168(12): 866
 28. Nicolè S, Mengoli C, Marini G, Coletto D, Cavinato S, Marinello S, Cattelan A. Characteristics of AIDS-related and non-AIDS-related cancers in an Italian cohort of HIV patients in the period 1996–2018. *J Int AIDS Soc* 2018; 21(S8): 124
 29. Cobucci RNO, Lima PH, de Souza PC, Costa VV, Cornetta M da C de M, Fernandes JV, Gonçalves AK. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review. *J Infect Public Health* 2015; 8(1): 1–10
 30. Schmidt C. The Cancer-HIV/AIDS Treatment Conundrum. *JNCI J Natl Cancer Inst* 2010; 102(21): 1615–1617
 31. Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, Klein D, Towner WJ, Dubrow R, Quesenberry CP, Neugebauer RS, Abrams DI. HIV Infection, Immunodeficiency, Viral Replication, and the Risk of Cancer. *Cancer Epidemiol Biomarkers Prev* 2011; 20(12): 2551–2559
 32. Baker J V, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, Cavert WP, Henry WK, Neaton JD, Terry Beinr Community Programs for Clinical Research on AIDS (CPCRA). CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. *AIDS* 2008; 22(7): 841–848
 33. Monforte A d'Arminio, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD, Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. *AIDS* 2008; 22(16): 2143–2153
 34. Kesselring A, Gras L, Smit C, van Twillert G, Verbon A, de Wolf F, Reiss P, Wit F. Immunodeficiency as a Risk Factor for Non-AIDS-Defining Malignancies in HIV-1-Infected Patients Receiving Combination

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Antiretroviral Therapy. *Clin Infect Dis* 2011; 52(12): 1458–1465
35. Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. *J Acquir Immune Defic Syndr* 2009; 52(2): 203–208
36. Engels EA, Brock M V., Chen J, Hooker CM, Gillison M, Moore RD. Elevated Incidence of Lung Cancer Among HIV-Infected Individuals. *J Clin Oncol* 2006; 24(9): 1383–1388
37. Shiels MS, Cole SR, Mehta SH, Kirk GD. Lung Cancer Incidence and Mortality Among HIV-Infected and HIV-Uninfected Injection Drug Users. *JAIDS J Acquir Immune Defic Syndr* 2010; 55(4): 510–515
38. Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Gupta N, Johung KL, Klopp A, LaCase AS, Lin C, Makarova-Rusher O V., Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, Palella F, Ratner L, Rizza S, Rudek MA, Taylor J, Tomlinson B, Wang C-CJ, Dwyer MA, Freedman-Cass DA. Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Cancer Netw* 2018; 16(8): 986–1017
39. Coghill AE, Engels EA, Schymura MJ, Mahale P, Shiels MS. Risk of Breast, Prostate, and Colorectal Cancer Diagnoses Among HIV-Infected Individuals in the United States. *J Natl Cancer Inst* 2018; 110(9): 959–966
40. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT, Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. *Ann Intern Med* 2008; 148(10): 728–736
41. Dauby N, De Wit S, Delforge M, Necsos VC, Clumeck N. Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study. *J Int AIDS Soc* 2011; 14(1): 16
42. Marcus JL, Chao CR, Leyden WA, Xu L, Klein DB, Horberg MA, Towner WJ, Quesenberry CP, Abrams DI, Van Den Eeden SK, Silverberg MJ. Prostate Cancer Incidence and Prostate-Specific Antigen Testing Among HIV-Positive and HIV-Negative Men. *JAIDS J Acquir Immune Defic Syndr* 2014; 66(5): 495–502
43. Stone TW, McPherson M, Gail Darlington L. Obesity and Cancer: Existing and New Hypotheses for a Causal Connection. *EBioMedicine* 2018; 30: 14–28
44. Trushin SA, Algeciras-Schimmich A, Vlahakis SR, Bren GD, Warren S, Schnepfle DJ, Badley AD. Glycoprotein 120 Binding to CXCR4 Causes p38-Dependent Primary T Cell Death That Is Facilitated by, but Does Not Require Cell-Associated CD4. *J Immunol* 2007; 178(8): 4846–4853
45. Anand AR, Ganju RK. HIV-1 gp120-mediated Apoptosis of T Cells Is Regulated by the Membrane Tyrosine Phosphatase CD45. *J Biol Chem* 2006; 281(18): 12289–12299
46. Cummins NW, Badley AD. Mechanisms of HIV-associated lymphocyte apoptosis: 2010. *Cell Death Dis* 2010; 1(11): e99
47. Liu Z, Qiao L, Zhang Y, Zang Y, Shi Y, Liu K, Zhang X, Lu X, Yuan L, Su B, Zhang T, Wu H, Chen D. ASPP2 Plays a Dual Role in gp120-Induced Autophagy and Apoptosis of Neuroblastoma Cells. *Front Neurosci* 2017; 11: 150
48. Endo M, Inatsu A, Hashimoto K, Takamune N, Shoji S, Misumi S. Human immunodeficiency virus-induced apoptosis of human breast cancer cells via CXCR4 is mediated by the viral envelope protein but does not require CD4. *Curr HIV Res* 2008; 6(1): 34–42
49. Bumpers HL, Huang M-B, Powell M, Grizzle WE, Lillard J, Okoli J, Bond VC. Effects of HIV-1 Nef, a cytotoxic viral protein, on the growth of primary colorectal cancer. *Cancer Biol Ther* 2005; 4(1): 72–76
50. Harrington W, Bond V, Huang MB, Powell M, Lillard J, Manne U, Bumpers H, Bumpers H. HIV Nef-M1 Effects on Colorectal Cancer Growth in Tumor-induced Spleens and Hepatic Metastasis. *Mol Cell Pharmacol* 2009; 1(2): 85–91
51. Singh S, Bond VC, Powell M, Singh UP, Bumpers HL, Grizzle WE, Lillard JW, Jr. CXCR4-gp120-IIIIB interactions induce caspase-mediated apoptosis of prostate cancer cells and inhibit tumor growth. *Mol Cancer Ther* 2009; 8(1): 178
52. Marcus JL, Chao C, Leyden WA, Xu L, Yu J, Horberg MA, Klein D, Towner WJ, Quesenberry CP, Abrams DI, Silverberg MJ. Survival among HIV-Infected and HIV-Uninfected Individuals with Common Non-AIDS-Defining Cancers. *Cancer Epidemiol Biomarkers Prev* 2015; 24(8): 1167–1173
53. Coghill AE, Pfeiffer RM, Shiels MS, Engels EA. Excess Mortality among HIV-Infected Individuals with Cancer in the United States. *Cancer Epidemiol Biomarkers Prev* 2017; 26(7): 1027–1033
54. Zucchetto A, Virdone S, Taborelli M, Grande E, Camoni L, Pappagallo M, Regine V, Grippo F, Polesel J, Dal Maso L, Suligoi B, Frova L, Serraino D. Non-AIDS-Defining Cancer Mortality. *JAIDS J Acquir Immune Defic Syndr* 2016; 73(2): 190–196
55. Suneja G, Shiels MS, Angulo R, Copeland GE, Gonsalves L, Hakenewerth AM, Macomber KE, Melville SK, Engels EA. Cancer Treatment Disparities in HIV-Infected Individuals in the United States. *J Clin Oncol* 2014; 32(22): 2344–2350
56. Hleyhel M, Belot A, Bouvier A-M, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger J-L, Dupont C,

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
- Lavolé A, Pradier C, Salmon D, Simon A, Martinez V, Spano J-P, Costagliola D, Grabar S. Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRSCO4 cohort. *Int J Cancer* 2015; 137(10): 2443–2453
57. Cingolani A, Cozzi Lepri A, Teofili L, Galli L, Mazzotta V, Baldin GM, Hohaus S, Bandera A, Alba L, Galizzi N, Castagna A, D'arminio Monforte A, Antinori A, ICONA Foundation Study group on behalf of IFS. Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. *PLoS One* 2017; 12(10): e0186549
58. Dryden-Peterson S, Bvochora-Nsingo M, Suneja G, Efstathiou JA, Grover S, Chiyapo S, Ramogola-Masire D, Kebabonye-Pusoentsi M, Clayman R, Mapes AC, Tapela N, Asmelash A, Medhin H, Viswanathan AN, Russell AH, Lin LL, Kayembe MKA, Mmalane M, Randall TC, Chabner B, Lockman S. HIV Infection and Survival Among Women With Cervical Cancer. *J Clin Oncol* 2016; 34(31): 3749–3757
59. Leitch H, Trudeau M, Routy J-P. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy. *HIV Clin Trials* 2003; 4(2): 107–114
60. Hoffmann C, Tabrizian S, Wolf E, Eggers C, Stoehr A, Plettenberg A, Buhk T, Stellbrink HJ, Horst HA, Jäger H, Rosenkranz T. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. *AIDS* 2001; 15(16): 2119–2127
61. Castillo JJ, Echenique IA. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: A pooled analysis of 15 prospective studies. *Am J Hematol* 2012; 87(3): 330–333
62. Uldrick TS, Pipkin S, Scheer S, Hessel NA. Risk factors for death and temporal trends in overall survival in patients with AIDS-associated primary central nervous system lymphoma (AIDS-PCNSL). *Infect Agent Cancer* 2012; 7(S1): O18
63. Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O, Vultaggio G, Tirelli U. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. *Cancer* 2001; 91(1): 155–163
64. Martinez V, Caumes E, Gambotti L, Ittah H, Morini J-P, Deleuze J, Gorin I, Katlama C, Bricaire F, Dupin N. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. *Br J Cancer* 2006; 94(7): 1000–1006
65. Wong AYJ, Marcotte S, Laroche M, Sheehan NL, Kukreti V, Routy J-P, Lemieux B, Seki JT, Rouleau D, Tseng A. Safety and efficacy of CHOP for treatment of diffuse large B-cell lymphoma with different combination antiretroviral therapy regimens: SCULPT study. *Antivir Ther* 2013; 18(5): 699–707
66. Ibrahim K, Milliken S. Protease Inhibitor Vs. Non-Protease Inhibitor Based Antiretroviral Therapy In HIV-Infected Patients With Hodgkin and Non-Hodgkin Lymphoma Receiving Chemotherapy. *Blood* 2013; 122(21)
67. Cattelan AM, Calabrò ML, Gasperini P, Aversa SM, Zanchetta M, Meneghetti F, De Rossi A, Chieco-Bianchi L. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. *J Natl Cancer Inst Monogr* 2001;(28): 44–49
68. Pinto-Almeida T, Torres T, Rosmaninho A, Sanches M, Alves R, Caetano M, Selores M. Letter: Penile Kaposi sarcoma: A case of complete resolution with highly active antiretroviral therapy alone. *Dermatol Online J* 2011; 17(6): 12
69. Kumarasamy N, Venkatesh KK, Devaleenol B, Poongulali S, Ahilasamy N. Regression of Kaposi's sarcoma lesions following highly active antiretroviral therapy in an HIV-infected patient. *Int J STD AIDS* 2008; 19(11): 786–788
70. Leder HA, Galor A, Peters GB, Kedhar SR, Dunn JP, Thorne JE. Resolution of conjunctival Kaposi sarcoma after institution of highly active antiretroviral therapy alone. *Br J Ophthalmol* 2008; 92(1): 151
71. Hallit RR, Afridi M, Sison R, Szabela MEY, Bajaj N, Alchaa R, Hallit S, Awkar N, Boghossian J, Slim J. AIDS-related lymphoma: resolution with antiretroviral therapy alone. *J Int Assoc Provid AIDS Care* 2014; 13(4): 313–315
72. Lim DH, Rhee J-Y, Park KW. Stage IV advanced diffuse large B-cell lymphoma in human immunodeficiency virus infection with achieving cure by using highly active antiretroviral therapy alone: a case report. *Int J STD AIDS* 2017; 28(9): 932–936
73. Travi G, Ferreri AJM, Cinque P, Gerevini S, Ponzoni M, Terreni MR, Lazzarin A, Crippa F. Long-term remission of HIV-associated primary CNS lymphoma achieved with highly active antiretroviral therapy alone. *J Clin Oncol* 2012; 30(10): e119-21
74. Katsidzira L, Ramsay A, Makunike-Mutasa R, Borok M. Complete regression of early diffuse B-cell lymphoma in an HIV-positive patient on antiretroviral therapy alone. *Int J STD AIDS* 2011; 22(7): 409–410
75. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. *AIDS* 1998; 12(12): 1459–1464

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
76. Blitz S, Baxter J, Raboud J, Walmsley S, Rachlis A, Smaill F, Ferenczy A, Coutlée F, Hankins C, Money D, Canadian Women's HIV Study Group. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. 2013; 208(3)
77. Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, Aboobaker J, Coovadia HM. A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa. *JAIDS J Acquir Immune Defic Syndr* 2012; 60(2): 150–157
78. Sombogaard F, Franssen EJF, Terpstra WE, Kerver ED, van den Berk GEL, Crul M. Outcome effects of antiretroviral drug combinations in HIV-positive patients with chemotherapy for lymphoma: a retrospective analysis. *Int J Clin Pharm* 2018;
79. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-Related Burkitt's Lymphoma Versus Diffuse Large-Cell Lymphoma in the Pre-Highly Active Antiretroviral Therapy (HAART) and HAART Eras: Significant Differences in Survival With Standard Chemotherapy. *J Clin Oncol* 2005; 23(19): 4430–4438
80. Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, Terziroli B, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT, Swiss HIV Cohort Study. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. *Antivir Ther* 2007; 12(6): 931–939
81. Olszewski AJ, Castillo JJ. Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. *AIDS* 2016; 30(5): 787–796
82. Chiao EY, Giordano TP, Richardson P, El-Serag HB. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. *J Clin Oncol* 2008; 26(3): 474–479
83. Kato T, Ieki R, Saito E, Ota T, Yuasa K, Iguchi M, Okamura T, Shibuya M. A long-term survival case of small cell lung cancer in an HIV-infected patient. *Jpn J Clin Oncol* 2005; 35(6): 349–352
84. Modest GA, Cooley TP, Zacks JF. HIV and refractory anemia with excess blasts (RAEB). *Am J Hematol* 2002; 70(4): 318–319
85. Leng LK, Pancharoen C, Bunupuradah T, Thisyakorn U, Trinavarat P, Sosothikul D, Ananworanich J. Regression of a cervical spinal mass following highly active antiretroviral therapy (HAART) in child with advanced human immunodeficiency virus (HIV) disease. *J Med Assoc Thai* 2007; 90(9): 1937–1942
86. Vilchez RA, Finch CJ, Jorgensen JL, Butel JS. The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era. *Medicine (Baltimore)* 2003; 82(2): 77–81
87. Lavolé A, Chouaïd C, Baudrin L, Wislez M, Raguin G, Pialoux G, Girard P-M, Milleron B, Cadranel J. Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. *Lung Cancer* 2009; 65(3): 345–350
88. Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulaifa D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M, Dowlati A, Little RF, Ivy SP, Deeken JF. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. *Cancer* 2014; 120(8): 1194–1202
89. Berretta M, Caraglia M, Martellotta F, Zappavigna S, Lombardi A, Fierro C, Atripaldi L, Muto T, Valente D, De Paoli P, Tirelli U, Di Francia R. Drug-Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV Infection. *Front Pharmacol* 2016; 7: 71
90. Torres HA, Rallapalli V, Saxena A, Granwehr BP, Viola GM, Ariza-Heredia E, Adachi JA, Chemaly RF, Marfatia R, Jiang Y, Mahale P, Kyvernitakis A, Fanale MA, Mulanovich V. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer. *Clin Microbiol Infect* 2014; 20(10): O672–O679
91. Mounier N, Katlama C, Costagliola D, Chichmanian R-M, Spano J-P. Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. *Crit Rev Oncol Hematol* 2009; 72(1): 10–20
92. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. *Curr Opin Oncol* 2009; 21(5): 445–454
93. Francia R Di, Fierro C, Paolo M Di, WCRJ SS-, 2015 undefined. Selected pharmacogenetic panel test for toxicity prevention of drug-drug interactions between Highly Active Antiretroviral Therapy (HAART) and antiblastic. *World cancer Res J* 2015; 2(1): e492
94. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV [Internet]. 2019
95. Crum-Cianflone NF, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Roediger MP, Agan B, Wegner S. The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. *J Acquir Immune Defic Syndr* 2009; 51(3): 305–309
96. Boettiger DC, Sabin CA, Grulich A, Ryom L, Bonnet F, Reiss P, Monforte A d'Arminio, Kirk O, Phillips A, Bower M, Fätkenheuer G, Lundgren JD, Law M, Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group. Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? *AIDS* 2016; 30(10): 1629–1637
97. Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, d'Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C, D:A:D study group. Cancer Risk and Use of Protease Inhibitor or Nucleoside Reverse Transcriptase Inhibitor–Based Combination Antiretroviral Therapy. *JAIDS J Acquir Immune Defic Syndr* 2015; 68(5): 568–577
98. Bohlius J, Valeri F, Maskew M, Prozesky H, Garone D, Sengayi M, Fox MP, Davies M-A, Egger M. Kaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era. *Int J Cancer* 2014; 135(11): 2644–2652
99. Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, Antunes F, Stellbrink H-J, Phillips AN, Lundgren JD. The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003. *Cancer* 2004; 100(12): 2644–2654
100. Chao C, Leyden WA, Xu L, Horberg MA, Klein D, Towner WJ, Quesenberry CP, Abrams DI, Silverberg MJ. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. *AIDS* 2012; 26(17): 2223–2231
101. Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K, CASCADE Collaboration. The C. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. *J Natl Cancer Inst* 2010; 102(11): 784–792
102. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, Blazes DL, Agan BK, Armstrong A, Fraser S, Crum NF. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. *Cancer* 2005; 104(7): 1505–1511
103. Clifford GM, Rickenbach M, Lise M, Dal Maso L, Battegay M, Bohlius J, Boffi El Amari E, Karrer U, Jundt G, Bordoni A, Ess S, Franceschi S, Swiss HIV Cohort Study. Hodgkin lymphoma in the Swiss HIV Cohort Study. *Blood* 2009; 113(23): 5737–5742
104. Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Papanizos V, Miro JM, Obel N, Prins M, Chêne G, Egger M, Collaboration of Observational HIV Epidemiological Research Europe. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes. *Blood* 2011; 117(23): 6100–6108
105. Lanoy E, Rosenberg PS, Fily F, Lascaux A-S, Martinez V, Partisani M, Poizot-Martin I, Rouveix E, Engels EA, Costagliola D, Goedert JJ, FHDH-ANRS CO4. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. *Blood* 2011; 118(1): 44–49
106. Cheng Z, Shan F, Liu J, Shi Y, Zhang Z, Wu G. Clinical and computed tomography findings in Chinese lung cancer patients with HIV infection: a multi-center study. *Thorac cancer* 2017; (no pagina(3): 238–245
107. Bruyand M, Le Marec F, Lavole A, Leffondre K, Spano JP, Le Moing V, Tattevin P, March L, Cadranet J, Bonnet F, Guiguet M. Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients: a nested case-control study. *AIDS* 2015; 29(9): 1105–1109
108. Kirk GD, Merlo C, O'Driscoll P, Mehta SH, Galai N, Vlahov D, Samet J, Engels EA. HIV Infection Is Associated with an Increased Risk for Lung Cancer, Independent of Smoking. *Clin Infect Dis* 2007; 45(1): 103–110
109. van der Snoek EM, van der Ende ME, den Hollander JC, Schutten M, Neumann HAM, van Doornum GJJ. Use of Highly Active Antiretroviral Therapy Is Associated With Lower Prevalence of Anal Intraepithelial Neoplastic Lesions and Lower Prevalence of Human Papillomavirus in HIV-Infected Men Who Have Sex With Men. *Sex Transm Dis* 2012; 39(7): 495–500
110. Duncan KC, Chan KJ, Chiu CG, Montaner JSG, Coldman AJ, Cescon A, Au-Yeung CG, Wiseman SM, Hogg RS, Press NM. HAART slows progression to anal cancer in HIV-infected MSM. *AIDS* 2015; 29(3): 305–311
111. Crum-Cianflone NF, Hullsiek KH, Marconi VC, Ganesan A, Weintrob A, Barthel R V, Agan BK, Infectious Disease Clinical Research Program HIV Working Group. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. *AIDS* 2010; 24(4): 535–543
112. Pappou EP, Magruder JT, Fu T, Hicks CW, Herman JM, Fang S, Wick EC, Safar B, Gearhart SL, Efron JE. Prognostic and Predictive Clinicopathologic Factors of Squamous Anal Canal Cancer in HIV-Positive and HIV-Negative Patients: Does HAART Influence Outcomes? *World J Surg* 2018; 42(3): 876–883
113. Sahasrabudhe V V., Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among

- 1
2 individuals with acquired immunodeficiency syndrome in the United States. *Cancer* 2012; 118(24): 6226–
3 6233
- 4 114. Olivero OA. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. *Environ Mol*
5 *Mutagen* 2007; 48(3–4): 215–223
- 6 115. Benhammou V, Warszawski J, Bellec S, Doz F, André N, Lacour B, Levine M, Bavoux F, Tubiana R,
7 Mandelbrot L, Clavel J, Blanche S, ANRS-Enquête Périnatale Française. Incidence of cancer in children
8 perinatally exposed to nucleoside reverse transcriptase inhibitors. *AIDS* 2008; 22(16): 2165–2177
- 9 116. Brogly S, Williams P, Seage GR, Van Dyke R. In utero nucleoside reverse transcriptase inhibitor exposure
10 and cancer in HIV-uninfected children: an update from the pediatric AIDS clinical trials group 219 and
11 219C cohorts. *J Acquir Immune Defic Syndr* 2006; 41(4): 535–536
- 12 117. Hleyhel M, Goujon S, Delteil C, Vasiljevic A, Luzi S, Stephan J-L, Reliquet V, Jannier S, Tubiana R,
13 Dollfus C, Faye A, Mandelbrot L, Clavel J, Warszawski J, Blanche S, ANRS French Perinatal Cohort Study
14 Group. Risk of cancer in children exposed to didanosine in utero. *AIDS* 2016; 30(8): 1245–1256
- 15 118. Hleyhel M, Goujon S, Sibiude J, Tubiana R, Dollfus C, Faye A, Mandelbrot L, Clavel J, Warszawski J,
16 Blanche S, ANRS French Perinatal Cohort study Group. Risk of cancer in children exposed to antiretroviral
17 nucleoside analogues *in utero* : The french experience. *Environ Mol Mutagen* 2017;
- 18 119. Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Bower M, Gazzard B. A comparison of
19 regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing
20 Kaposi's sarcoma. *AIDS* 2003; 17(11): F17-22
- 21 120. Stebbing J, Portsmouth S, Nelson M, Mandalia S, Kandil H, Alexander N, Davies L, Brock C, Bower M,
22 Gazzard B. The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma. *Int J cancer* 2004;
23 108(4): 631–633
- 24 121. Gantt S, Cattamanchi A, Krantz E, Magaret A, Selke S, Kuntz SR, Huang M-L, Corey L, Wald A, Casper C.
25 Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based
26 antiretroviral therapy. *J Clin Virol* 2014; 60(2): 127–132
- 27 122. Gill J, Bourboulia D, Wilkinson J, Hayes P, Cope A, Marcelin A-G, Calvez V, Gotch F, Boshoff C, Gazzard
28 B. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus
29 infection in patients with and without Kaposi sarcoma. *J Acquir Immune Defic Syndr* 2002; 31(4): 384–390
- 30 123. Bani-Sadr F, Fournier S, Molina JM. Relapse of Kaposi's sarcoma in HIV-infected patients switching from
31 a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral
32 therapy regimen. *AIDS* 2003; 17(10): 1580–1581
- 33 124. Pappas VA, Kyriakis KP, Kourkounti S, Leuow K, Daskalakis E, Katsambas A. The Influence of a
34 HAART regimen on the expression of HIV-associated Kaposi sarcoma. *J Acquir Immune Defic Syndr* 2008;
35 49(1): 111
- 36 125. Ridolfo AL, Corbellino M, Tosca N, Capelletti A, Scalarmogna C, Galli M, Parravicini C. Is switching
37 protease inhibitor-based effective antiretroviral therapy safe in patients with AIDS-associated Kaposi's
38 sarcoma? *AIDS* 2004; 18(8): 1224–1226
- 39 126. Philibert P, Chiche L, Caillères S, Allemand J, Rebaudet S, Delord M, Stavris C, Retornaz F, Khiri H,
40 Halfon P. HHV8 and Kaposi's sarcoma: should we really give up protease inhibitors in all HIV-infected
41 patients? *AIDS* 2017; 31(15): 2167–2169
- 42 127. Simonetti FR, Ricaboni D, Cattaneo D, Micheli V, Rusconi S, Gervasoni C. Relapse of Kaposi's Sarcoma
43 and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based
44 antiretroviral therapy. *J Clin Virol* 2016; 74: 75–77
- 45 128. Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H,
46 Fätkenheuer G, Yust I, Schmid P, Gottfredsson M, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B,
47 Radoi R, Losso MH, Lundgren JD, Mocroft A, EuroSIDA Study Group the ES. Incidence of cancer and
48 overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination
49 antiretroviral therapy regimens. *HIV Med* 2018; 19(2): 102–117
- 50 129. Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E,
51 Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR, AIDS Clinical Trials Group
52 5211 Team. Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected,
53 Treatment-Experienced Patients: AIDS Clinical Trials Group 5211. *J Infect Dis* 2007; 196(2): 304–312
- 54 130. Caseiro MM, Nelson M, Diaz RS, Gathe J, de Andrade Neto JL, Slim J, Solano A, Netto EM, Mak C, Shen
55 J, Greaves W, Dunkle LM, Vilchez RA, Zeinecker J. Vicriviroc plus optimized background therapy for
56 treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomized phase III trials.
57 *J Infect* 2012; 65(4): 326–335
- 58 131. Gulick RM, Fätkenheuer G, Burnside R, Hardy WD, Nelson MR, Goodrich J, Mukwaya G, Portsmouth S,
59 Heera JR. Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients. *J*
60 *Acquir Immune Defic Syndr* 2014; 65(1): 78-81
132. Krishnan S, Schouten JT, Jacobson DL, Benson CA, Collier AC, Koletar SL, Santana J, Sattler FR,

- Mitsuyasu R, ACTG-ALLRT Protocol Team. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. *Oncology* 2011; 80(1–2): 42–49
133. Mbang PA, Kowalkowski MA, Amirian ES, Giordano TP, Richardson PA, Hartman CM, Chiao EY. Association between Time on Protease Inhibitors and the Incidence of Squamous Cell Carcinoma of the Anus among U.S. Male Veterans. *Sahasrabudhe V, editor. PLoS One* 2015; 10(12): e0142966
134. Lusivika-Nzinga C, Selinger-Leneman H, Grabar S, Costagliola D, Carrat F. Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination. *BMC Med Res Methodol* 2017; 17(1): 160
135. Grabar S, Selinger-Leneman H, Abramowitz L, Boue F, Mary-Krause M, Duvivier C, Rouveix E, Poizot-Martin I, Costagliola D. Anal cancer risk and use of a protease inhibitor: a nested case-control study within the ANRS CO4-FHDH cohort. *J Int AIDS Soc* 2018; 21(S8): 121–122
136. Gills JJ, LoPiccolo J, Tsurutani J, Shoemaker RH, Best CJM, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA. Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo. *Clin Cancer Res* 2007; 13(17): 5183–5194
137. Srirangam A, Mitra R, Wang M, Gorski JC, Badve S, Baldrige L, Hamilton J, Kishimoto H, Hawes J, Li L, Orschell CM, Srour EF, Blum JS, Donner D, Sledge GW, Nakshatri H, Potter DA. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. *Clin Cancer Res* 2006; 12(6): 1883–1896
138. Shim JS, Rao R, Beebe K, Neckers L, Han I, Nahta R, Liu JO. Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir. *JNCI J Natl Cancer Inst* 2012; 104(20): 1576–1590
139. Soprano M, Sorriento D, Rusciano MR, Maione AS, Limite G, Forestieri P, D'Angelo D, D'Alessio M, Campiglia P, Formisano P, Iaccarino G, Bianco R, Illario M. Oxidative stress mediates the antiproliferative effects of Nelfinavir in breast cancer cells. *PLoS One* 2016; 11(6): e0155970
140. Koltai T. Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity. *F1000Research* 2015; 4: 9
141. Maksimovic-Ivanic D, Fagone P, McCubrey J, Bendtzen K, Mijatovic S, Nicoletti F. HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives? *Int J cancer* 2017; 140(8): 1713–1726
142. Bernstein WB, Dennis PA. Repositioning HIV protease inhibitors as cancer therapeutics. *Curr Opin HIV AIDS* 2008; 3(6): 666–675
143. Goda J, Pachpor T, Basu T, Chopra S, Gota V. Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers. *Indian J Med Res* 2016; 143(2): 145
144. Faes S, Dormond O. PI3K and AKT: Unfaithful Partners in Cancer. *Int J Mol Sci* 2015; 16(9): 21138–21152
145. Radisavljevic Z. AKT as Locus of Cancer Phenotype. *J Cell Biochem* 2015; 116(1): 1–5
146. Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. *Ann Med* 2014; 46(6): 372–383
147. Polivka J, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. *Pharmacol Ther* 2014; 142(2): 164–175
148. Zheng H-C. The molecular mechanisms of chemoresistance in cancers. *Oncotarget* 2017; 8(35): 59950–59964
149. Farrand L, Oh S-W, Song YS, Tsang BK. Phytochemicals: a multitargeted approach to gynecologic cancer therapy. *Biomed Res Int* 2014; 2014: 890141
150. Miyata Y, Nakamoto H, Neckers L. The therapeutic target Hsp90 and cancer hallmarks. *Curr Pharm Des* 2013; 19(3): 347–365
151. Kim JG, Lee SC, Kim O-H, Kim K-H, Song KY, Lee SK, Choi BJ, Jeong W, Kim S-J. HSP90 inhibitor 17-DMAG exerts anticancer effects against gastric cancer cells principally by altering oxidant-antioxidant balance. *Oncotarget* 2017; 8(34): 56473–56489
152. Manalo RVM, Medina PMB. The endoplasmic reticulum stress response in disease pathogenesis and pathophysiology. *Egypt J Med Hum Genet* 2018; 19(2): 59–68
153. Arodola O, Soliman M. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses. *Drug Des Devel Ther* 2015; 9: 6055
154. Lutz WK. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination? *Toxicol Lett* 2009; 190(3): 239–242
155. Gantt S, Carlsson J, Ikoma M, Gachelet E, Gray M, Geballe AP, Corey L, Casper C, Lagunoff M, Vieira J. The HIV Protease Inhibitor Nelfinavir Inhibits Kaposi's Sarcoma-Associated Herpesvirus Replication In Vitro. *Antimicrob Agents Chemother* 2011; 55(6): 2696–2703
156. Brown JA, Pack LR, Fowler JD, Suo Z. Pre-steady-state kinetic analysis of the incorporation of anti-HIV

- nucleotide analogs catalyzed by human X- and Y-family DNA polymerases. *Antimicrob Agents Chemother* 2011; 55(1): 276–283
157. Perna A, Lucariello A, Sellitto C, Agliata I, Carleo MA, Sangiovanni V, Esposito V, Guerra G, Cobellis L, De Luca A. Different Cell Cycle Modulation in SKOV-3 Ovarian Cancer Cell Line by Anti-HIV Drugs. *Oncol Res Featur Preclin Clin Cancer Ther* 2017; 25(9): 1617–1624
158. Carlini F, Ridolfi B, Molinari A, Parisi C, Bozzuto G, Toccaceli L, Formisano G, De Orsi D, Paradisi S, Grober OMV, Ravo M, Weisz A, Arcieri R, Vella S, Gaudi S. The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines. Creighton C, editor. 2010; 5(12): e14221
159. Landriscina M, Spadafora C, Cignarelli M, Barone C. Anti-tumor activity of non-nucleosidic reverse transcriptase inhibitors. *Curr Pharm Des* 2007; 13(7): 737–747
160. Brüning A, Burger P, Gingelmaier A, Mylonas I. The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells. *Invest New Drugs* 2012; 30(4): 1389–1395
161. Crespan E, Garbelli A, Amoroso A, Maga G. Exploiting the nucleotide substrate specificity of repair DNA polymerases to develop novel anticancer agents. *Molecules* 2011; 16(9): 7994–8019
162. Young MJ. Off-Target Effects of Drugs that Disrupt Human Mitochondrial DNA Maintenance. *Front Mol Biosci* 2017; 4: 74
163. Xiao-Jie L, Hui-Ying X, Qi X, Jiang X, Shi-Jie M. LINE-1 in cancer: multifaceted functions and potential clinical implications. *Genet Med* 2016; 18(5): 431–439
164. Mangiacasale R, Pittoggi C, Sciamanna I, Careddu A, Mattei E, Lorenzini R, Travaglini L, Landriscina M, Barone C, Nervi C, Lavia P, Spadafora C. Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation. *Oncogene* 2003; 22(18): 2750–2761
165. Hecht M, Harrer T, Korber V, Sarpong E, Moser F, Fiebig N, Schwegler M, Stüßl M, Fietkau R, Distel L. Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation. *Oncol Lett* 2017; 15(2): 1728–1736
166. Landriscina M, Bagalà C, Piscazzi A, Schinzari G, Quirino M, Fabiano A, Bianchetti S, Cassano A, Sica G, Barone C. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. *Prostate* 2009; 69(7): 744–754
167. Hecht M, Erber S, Harrer T, Klinker H, Roth T, Parsch H, Fiebig N, Fietkau R, Distel L V. Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells. Menéndez-Arias L, editor. *PLoS One* 2015; 10(6): e0130277
168. Brüning A, Jückstock J, Kost B, Tsikouras P, Weissenbacher T, Mahner S, Mylonas I. Induction of DNA damage and apoptosis in human leukemia cells by efavirenz. *Oncol Rep* 2017; 37(1): 617–621
169. Sciamanna I, Landriscina M, Pittoggi C, Quirino M, Mearelli C, Beraldi R, Mattei E, Serafino A, Cassano A, Sinibaldi-Vallebona P, Garaci E, Barone C, Spadafora C. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. *Oncogene* 2005; 24(24): 3923–3931
170. Ulrike K, Markus H, Thomas H, Ellen H, Barbara S, Rainer F, Distel L V. NNRTI-based antiretroviral therapy may increase risk of radiation induced side effects in HIV-1-infected patients. *Radiother Oncol* 2015; 116(2): 323–330
171. Varadarajan J, McWilliams MJ, Hughes SH. Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations. *Proc Natl Acad Sci* 2013; 110(36): 14747–14752
172. Varadarajan J, McWilliams MJ, Mott BT, Thomas CJ, Smith SJ, Hughes SH. Drug resistant integrase mutations cause aberrant HIV integrations. *Retrovirology* 2016; 13(1): 71
173. Williamson EA, Damiani L, Leitao A, Hu C, Hathaway H, Oprea T, Sklar L, Shaheen M, Bauman J, Wang W, Nickoloff JA, Lee S-H, Hromas R. Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapy. *Cancer Res* 2012; 72(23): 6200–6208
174. Pervaiz A, Zepp M, Mahmood S, Ali DM, Berger MR, Adwan H. CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer. *Cell Oncol* 2018;
175. Casagrande N, Borghese C, Visser L, Mongiat M, Colombatti A, Aldinucci D. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth. *Haematologica* 2018; haematol.2018.196725
176. Velasco-Velazquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, Pestell RG. CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells. *Cancer Res* 2012; 72(15): 3839–3850
177. Tanabe Y, Sasaki S, Mukaida N, Baba T. Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancer-associated fibroblast accumulation. *Oncotarget* 2016; 7(30): 48335–48345
178. Sicoli D, Jiao X, Ju X, Velasco-Velazquez M, Ertel A, Addya S, Li Z, Andò S, Fatatis A, Paudyal B, Cristofanilli M, Thakur ML, Lisanti MP, Pestell RG. CCR5 receptor antagonists block metastasis to bone of v-*Src* oncogene-transformed metastatic prostate cancer cell lines. *Cancer Res* 2014; 74(23): 7103–7114
179. Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J,

- Lasitschka F, al. et, Lerchl T, Luckner-Minden C, Ulrich A, Koch M, Weitz J, Schneider M, Buechler MW, Zitvogel L, Herrmann T, Benner A, Kunz C, Luecke S, Springfield C, Grabe N, Falk CS, Jaeger D. Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. *Cancer Cell* 2016; 29(4): 587-601
180. Monini P, Sgadari C, Grosso MG, Bellino S, Di Biagio A, Toschi E, Bacigalupo I, Sabbatucci M, Cencioni G, Salvi E, Leone P, Ensoli B. Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. *AIDS* 2009; 23(4): 534-538
181. Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A, Sauer R, Hohenberger W, McKenna WG. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. *J Clin Oncol* 2008; 26(16): 2699-2706
182. Rengan R, Mick R, Pryma D, Rosen MA, Lin LL, Maity AM, Evans TL, Stevenson JP, Langer CJ, Kucharczuk J, Friedberg J, Prendergast S, Sharkoski T, Hahn SM. A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Toxicities and Clinical Response. *J Thorac Oncol* 2012; 7(4): 709-715
183. Buijsen J, Lammering G, Jansen RLH, Beets GL, Wals J, Sosef M, Den Boer MO, Leijtens J, Riedl RG, Theys J, Lambin P. Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. *Radiother Oncol* 2013; 107(2): 184-188
184. Driessen C, Muller R, Novak U, Cantoni N, Betticher D, Mach N, Gregor M, Samaras P, Berset C, Rondeau S, al. et, Müller R, Novak U, Cantoni N, Betticher D, Mach N, Gregor M, Samaras P, Berset C, Rondeau S, Hawle H, Hitz F, Pabst T, Zander T. The HIV protease inhibitor nelfinavir in combination with bortezomib and dexamethasone (NVd) has excellent activity in patients with advanced, proteasome inhibitor-refractory multiple myeloma: a multicenter phase II trial (SAKK 39/13). *Blood Conf 58th Annu Meet Am Soc Hematol ASH 2016 United States Conf start 20161203 Conf end 20161206 2016*; 128(22) (no pagination)
185. Blumenthal GM, Gills JJ, Ballas MS, Bernstein WB, Komiya T, Dechowdhury R, Morrow B, Root H, Chun G, Helsabeck C, Steinberg SM, LoPiccolo J, Kawabata S, Gardner ER, Figg WD, Dennis PA. A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. *Oncotarget* 2014; 5(18): 8161-8172
186. Alonso-Basanta M, Fang P, Maity A, Hahn SM, Lustig RA, Dorsey JF. A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme. *J Neurooncol* 2014; 116(2): 365-372
187. Wilson JM, Fokas E, Dutton SJ, Patel N, Hawkins MA, Eccles C, Chu K-Y, Durrant L, Abraham AG, Partridge M, Woodward M, O'Neill E, Maughan T, McKenna WG, Mukherjee S, Brunner TB. ARCI: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. *Radiother Oncol* 2016; 119(2): 306-311
188. Hampson L, Maranga IO, Masinde MS, Oliver AW, Batman G, He X, Desai M, Okemwa PM, Stringfellow H, Martin-Hirsch P, Mwaniki AM, Gichangi P, Hampson IN. A Single-Arm, Proof-Of-Concept Trial of Lopimune (Lopinavir/Ritonavir) as a Treatment for HPV-Related Pre-Invasive Cervical Disease. Sahasrabudhe V, editor. *PLoS One* 2016; 11(1): e0147917
189. Modoni S, Landriscina M, Fabiano A, Fersini A, Urbano N, Ambrosi A, Cignarelli M. Reinduction of cell differentiation and I¹³¹I uptake in a poorly differentiated thyroid tumor in response to the reverse transcriptase (RT) inhibitor nevirapine. *Cancer Biother Radiopharm* 2007; 22(2): 289-295
190. Landriscina M, Modoni S, Fabiano A, Fersini A, Barone C, Ambrosi A, Cignarelli M. Cell differentiation and iodine-131 uptake in poorly differentiated thyroid tumour in response to nevirapine. *Lancet Oncol* 2006; 7(10): 877-879
191. Hoover AC, Milhem MM, Anderson CM, Sun W, Smith BJ, Hoffman HT, Buatti JM. Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial. *Head Neck* 2015; 37(5): 722-726
192. Houede N, Pulido M, Mourey L, Joly F, Ferrero J-M, Bellera C, Priou F, Lalet C, Laroche-Clary A, Raffin MC, Ichas F, Puech A, Piazza P V. A Phase II Trial Evaluating the Efficacy and Safety of Efavirenz in Metastatic Castration-Resistant Prostate Cancer. *Oncologist* 2014; 19(12): 1227-1228
193. Ahluwalia MS, Patton C, Stevens G, Tekautz T, Angelov L, Vogelbaum MA, Weil RJ, Chao S, Elson P, Suh JH, Barnett GH, Peereboom DM. Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas. *J Neurooncol* 2011; 102(2): 317-321
194. Mani D, Neil N, Israel R, Aboulafia DM. A retrospective analysis of AIDS-associated Kaposi's sarcoma in patients with undetectable HIV viral loads and CD4 counts greater than 300 cells/mm³. *J Int Assoc Physicians AIDS Care (Chic)* 2009; 8(5): 279-285
195. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, Grigg R, Hylton T, Pawlish KS, McNeel TS, Goedert JJ. Cancer risk in people infected with human immunodeficiency virus in the United States. *Int J Cancer* 2008; 123(1): 187-194
196. van Leeuwen MT, Vajdic CM, Middleton MG, McDonald AM, Law M, Kaldor JM, Grulich AE.

1
2 Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of
3 antiretroviral therapy. *AIDS* 2009; 23(16): 2183–2190
4 197. Wu Y, Yoder A. Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. Manchester M,
5 editor. *PLoS Pathog* 2009; 5(12): e1000520
6 198. European AIDS Clinical Society. EACS Guidelines 9.1 [Internet]. 2018
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Appendixes

Tables

Table 1. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors, protease inhibitors or integrase strand transfer inhibitors in preventing cancers in HIV-infected persons.

Type of cancer	Study design	Cohort size	Conclusion	Reference
ADCs				
ADCs, Kaposi's sarcoma alone, NHL alone	Prospective cohort study	42006	Nelfinavir = non-Nelfinavir-PI = NNRTI in cancer prevention	96
ADCs, Kaposi's sarcoma alone	Prospective cohort study	41762	PI = NNRTI in cancer prevention	97
NHL alone			NNRTI, but not PI, is associated with a lower risk	
Kaposi's sarcoma	Prospective cohort study	4480	Ritonavir = non-Ritonavir-PI = NNRTI in cancer prevention	120
Kaposi's sarcoma	Prospective cohort study	1204	PI = NNRTI in cancer prevention	119
Kaposi's sarcoma	Prospective cohort study	45	Kaposi's sarcoma relapse after switch from PI to NNRTI	124
ADCs, Kaposi's sarcoma alone, NHL alone	Retrospective cohort study	12872	PI = NNRTI in cancer prevention	100
ADCs	Retrospective cohort study	2499	Nelfinavir = Indinavir = other regimens in cancer prevention	95
Kaposi's sarcoma	Retrospective cohort study	91	PI = NNRTI in cancer incidence and clinical course	194
Kaposi's sarcoma	Case series	24	No Kaposi's sarcoma relapse after switching from PI to NNRTI	125
Kaposi's sarcoma	Case series	5	Kaposi's sarcoma relapse after switch from PI to NNRTI	123
Kaposi's sarcoma	Case report	1	PI switch to INSTI led to HHV8 viremia and sarcoma relapse	127
Kaposi's sarcoma	Case report	1	PI switch to INSTI led to HHV8 viremia, while INSTI switch back to PI resulted in a remission	126
NADCs				
Anal cancer	Prospective cohort study	72355	PI monotherapy, opposite to other antiretroviral therapy, is associated with increased cancer risk	134

NADCs, anal cancer alone	Prospective cohort study	42006	PI = NNRTI in cancer prevention, except for a higher risk of anal cancer with longer non-Nelfinavir PI, but not Nelfinavir or NNRTI	96
NADCs, anal cancer alone, HL alone	Prospective cohort study	41762	PI but not NNRTI, use is associated with increased cancer risk	97
Lung cancer, head and neck cancers			PI = NNRTI in cancer prevention	
NADCs, HL alone	Prospective cohort study	5076	NNRTI but not PI or NRTI therapy was associated with an increased risk of NADCs	2
NADCs	Prospective cohort study	3158	Initial PI = NNRTI = NRTI in cancer prevention	132
Virus-related, virus-unrelated NADCs	Retrospective cohort study	12872	PI = NNRTI in cancer prevention, except for a higher risk of anal cancer with longer PI, but not NNRTI	100
NADCs	Retrospective cohort study	2499	Nelfinavir = Indinavir = other regimens in cancer prevention	95
All cancers				
All cancers	Prospective cohort study	7971	Raltegravir (INSTI) is not associated with an increased risk of cancer compared with other treatment strategies	128

Abbreviations: INSTI, HIV-integrase strand transfer inhibitor-based antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy; PI, HIV-protease inhibitor-based antiretroviral therapy.

Table 2. Clinical trials of antiretroviral drugs in non-HIV related cancer treatment.

NCT number	Drug	Condition	Phase	Actual enrollment	Start date
HIV-protease inhibitors					
NCT00233948	Nelfinavir	Liposarcoma	I/II	29	March 2006
NCT01445106	Nelfinavir	Solid Tumors	I	28	December 2006
NCT00589056	Nelfinavir	Stage III Non-Small Cell Lung Cancer	I/II	55	June 2007
NCT01068327	Nelfinavir	Locally Advanced Pancreatic Cancer	I	46	November 2007
NCT00704600	Nelfinavir	Rectal Cancer	I/II	15	September 2008
NCT00694837	Nelfinavir	Glioblastoma	I/II	6	March 2009
NCT00915694	Nelfinavir	Glioblastoma Multiforme	I	23	April 2009
NCT01020292	Nelfinavir	Grade IV Glioma	I	31	April 2009
NCT01086332	Nelfinavir	Pancreatic Cancer	I	7	May 2009
NCT01079286	Nelfinavir	Advanced Cancers	I	18	June 2009

NCT01065844	Nelfinavir	Adenoid Cystic Cancer of the Head and Neck	II	15	October 2009
NCT01108666	Nelfinavir	Inoperable Stage III Non Small Cell Lung Cancer	I	72	March 2010
NCT01164709	Nelfinavir	Relapsed or Progressive Advanced Hematologic Cancer	I	18	July 2010
NCT01485731	Nelfinavir	Cervical Cancer	I	8	January 2012
NCT01555281	Nelfinavir	Progressive Multiple Myeloma	I/II	33	February 2012
NCT01925378	Nelfinavir	Cervical Intraepithelial Neoplasia	II	10	July 2012
NCT01728779	Nelfinavir	Oligometastases	II	40	June 2013
NCT01959672	Nelfinavir	Locally Advanced Pancreatic Cancer	II	12	September 2013
NCT02207439	Nelfinavir	Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Larynx, or Hypopharynx	II	28	July 2014
NCT02188537	Nelfinavir	Proteasome Inhibitor-nonresponsive Myeloma	II	34	December 2014
NCT02363829	Nelfinavir	Locally Advanced Cervical Cancer	I	6	February 2015
NCT02024009	Nelfinavir	Advanced Localised Pancreatic Cancer	I/II	289	March 2016
NCT03050060	Nelfinavir	Advanced Melanoma, Lung, or Kidney Cancer	II	120	June 2017
NCT03256916	Nelfinavir	Locally Advanced Carcinoma of Cervix	III	0	September 2017
NCT00637637	Ritonavir / Indinavir	Brain Metastases	II	60	September 2007
NCT01095094	Ritonavir / Lopinavir	Progressive or Recurrent High-Grade Glioma	II	19	January 2009
NCT01009437	Ritonavir	Breast Cancer	I/II	28	May 2010
NCT03066154	ModraDoc006/r (oral docetaxel with ritonavir)	High-risk Prostate Cancer	I	24	September 2016
NCT02770378	Ritonavir	Recurrent Glioblastoma	I	10	November 2016
NCT03136640	ModraDoc006/r (oral docetaxel with ritonavir)	Castration-resistant Prostate Cancer	I	20	April 2017
NCT03150368	ModraDoc006/r (oral	Advanced Solid Tumors	I	22	May 2017

	docetaxel with ritonavir)				
NCT03383692	Ritonavir	Advanced Solid Malignant Tumors	I	40	January 2018
Nucleoside reverse transcriptase inhibitors					
NCT03144804	Lamivudine	p53 Mutant Metastatic Colorectal Cancer	II	32	October 2017
Non-nucleoside reverse transcriptase inhibitors					
NCT00964002	Efavirenz	Metastatic Prostate Cancer	II	60	May 2008
NCT00964171	Efavirenz	Metastatic Pancreatic Cancer	II	72	August 2008
NCT01878890	Efavirenz	Solid Tumours or NHL	I	30	June 2011
Integrase strand transfer inhibitors					
NCT01275183	Raltegravir	Squamous Cell Carcinoma of Head and Neck	I	5	December 2010
CCR5 antagonist					
NCT01736813	Maraviroc	Metastatic Colorectal Cancer	I	12	November 2012
NCT03274804	Maraviroc	Metastatic Colorectal Cancer	I	20	April 2018

The studies on AIDS-, EBV-, HBV-, HCV-, HTLV-related cancers are excluded.

Table 3. Summary of the role of HAART in HIV-cancer relationship.

Parameter	All cancers	ADCs	NADCs	
			Virus-related	Virus-unrelated
Cancer incidence compared to the general population in the pre-HAART era	↑↑	↑↑↑	↑	= *
Cancer incidence compared to the general population in the HAART era	↑	↑↑	↑	↓
Cancer incidence in the HAART era compared to the pre-HAART era	↓	↓↓↓**	↑	↑
The risk of cancer with HAART use compared to no treatment	↓	↓↓↓	↑	=

* – due to a small cohort size and a large 95%-confidence interval

** – except Burkitt's lymphoma;

Sources:^{195,196} and other articles cited in the text.

Figure legends

Figure 1. Factors influencing the risk of cancer in HIV-infected people. Cancer risk factors are represented on the left. Immunosuppression and chronic inflammation, caused by HIV infection, predispose to tumorigenesis. Besides, HIV-infected population is more susceptible to cancer risk behavior (smoking, men who have sex with men, intravenous drug use, alcohol consumption) and coinfection with other oncogenic viruses. Some of these risk factors are modifiable. Factors that reduce cancer risk are represented on the right. Highly active antiretroviral therapy (HAART) restores the immunity and suppresses viral replication, it was also shown to possess preclinical antioncogenic activity; however, the clinical relevance of this activity remains to be elucidated.

Figure 2. Potential mechanisms of the antineoplastic effects of different classes of HAART drugs. **A.** PI3K/Akt pathway regulates growth, proliferation, survival, migration, and apoptosis. In cancer, PI3K/Akt activation inhibits apoptotic enzymes; promotes transcription regulation that increases growth, survival, proliferation, increases MMPs (migration, invasion, metastasis) and VEGF (angiogenesis) expression *via* mTOR and NF- κ B axes; causes chemo-/radiotherapy resistance by deregulation of DNA damage response. **PIs** inhibit the PI3K/Akt pathway, possibly through binding to Hsp90 and inhibiting its chaperone function. MMPs and VEGF are also Hsp90 clients destabilized by chaperone inhibition; overall, Hsp90 inhibition leads to misfolded protein aggregation, ER stress, apoptosis, and autophagy. CCR5 receptor promotes pro-oncogenic cascades as it also activates the PI3K/Akt pathway, thus **CCR5 antagonists** are also antioncogenic effectors. Other pathways implicated in CCR5 downstream signaling include phospholipase C- γ , Rac/CDC42/RhoA, JAK-STAT pathways (data not shown)¹⁹⁷. **B.** **NRTIs** and **NNRTIs** interfere with nuclear DNA integrity, mitochondrial DNA maintenance and oxidative stress, retrotransposon LINE-1 expansion, which makes them potential anticancer agents. LINE-1 promotes genome instability and contributes to carcinogenesis. **INSTIs** also inhibit the DNA-repair enzyme metnase involved in chemotherapy resistance. Abbreviations: CCR5, C-C chemokine receptor type 5; ER, endoplasmic reticulum; INSTI, HIV-integrase strand transfer inhibitor; LINE-1, long interspersed nuclear element-1; MMPs, matrix metalloproteinases; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, HIV-protease inhibitor; PI3K, phosphatidylinositol 3-kinase; ROS, reactive oxygen species; RT, reverse transcriptase; VEGF, vascular endothelial growth factor. ➤ - promoting downstream effect, ─┐ - inhibiting downstream effect, ─── - active pathway under the action of drugs, - - - - suppressed pathway under the action of drugs, ↪ - gene transcription, ⬆ and ⬇ - resulting effects of drugs on critical cellular cancer-related processes (activation and suppression, respectively).




Figure 1. Factors influencing the risk of cancer in HIV-infected people. Cancer risk factors are represented on the left. Immunosuppression and chronic inflammation, caused by HIV infection, predispose to tumorigenesis. Besides, HIV-infected population is more susceptible to cancer risk behavior (smoking, men who have sex with men, intravenous drug use, alcohol consumption) and coinfection with other oncogenic viruses. Some of these risk factors are modifiable. Factors that reduce cancer risk are represented on the right. Highly active antiretroviral therapy (HAART) restores the immunity and suppresses viral replication, it was also shown to possess preclinical antioncogenic activity; however, the clinical relevance of this activity remains to be elucidated.




Figure 2. Potential mechanisms of the antineoplastic effects of different classes of HAART drugs. A. PI3K/Akt pathway regulates growth, proliferation, survival, migration, and apoptosis. In cancer, PI3K/Akt activation inhibits apoptotic enzymes; promotes transcription regulation that increases growth, survival, proliferation, increases MMPs (migration, invasion, metastasis) and VEGF (angiogenesis) expression via mTOR and NF-κB axes; causes chemo-/radiotherapy resistance by deregulation of DNA damage response. PIs inhibit the PI3K/Akt pathway, possibly through binding to Hsp90 and inhibiting its chaperone function. MMPs and VEGF are also Hsp90 clients destabilized by chaperone inhibition; overall, Hsp90 inhibition leads to misfolded protein aggregation, ER stress, apoptosis, and autophagy. CCR5 receptor promotes pro-oncogenic cascades as it also activates the PI3K/Akt pathway, thus CCR5 antagonists are also antioncogenic effectors. Other pathways implicated in CCR5 downstream signaling include phospholipase C-γ, Rac/CDC42/RhoA, JAK-STAT pathways (data not shown). B. NRTIs and NNRTIs interfere with nuclear DNA integrity, mitochondrial DNA maintenance and oxidative stress, retrotransposon LINE-1 expansion, which makes them potential anticancer agents. LINE-1 promotes genome instability and contributes to carcinogenesis. INSTIs also inhibit the DNA-repair enzyme metnase involved in chemotherapy resistance. Abbreviations: CCR5, C-C chemokine

1
2
3 receptor type 5; ER, endoplasmic reticulum; INSTI, HIV-integrase strand transfer inhibitor; LINE-1, long
4 interspersed nuclear element-1; MMPs, matrix metalloproteinases; NNRTI, non-nucleoside reverse
5 transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, HIV-protease inhibitor; PI3K,
6 phosphatidylinositol 3-kinase; ROS, reactive oxygen species; RT, reverse transcriptase; VEGF, vascular
7 endothelial growth factor. - promoting downstream effect, □- inhibiting downstream effect, - active
8 pathway under the action of drugs, - suppressed pathway under the action of drugs, - gene transcription,
9 and - resulting effects of drugs on critical cellular cancer-related processes (activation and suppression,
10 respectively).
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60